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 ABSTRACT  
TITLE: Study of HLA DR and DQ types in patients with pemphigus vulgaris as compared to that 
in healthy subjects. 
DEPARTMENT: Dept. of Dermatology Venereology and Leprosy, Christian Medical College, 
Vellore. 
NAME OF THE CANDIDATE : Dr.Anuradha Priyadarshini 
DEGREE AND SUBJECT: MD DERMATOLOGY, VENEREOLOGY AND LEPROSY. 
NAME OF THE GUIDE: Dr.Renu George, Prof and Head, Dept. of Dermatology, Venereology 
and Leprosy, Christian Medical College, Vellore.  
 
Objectives: Pemphigus is an acquired immunobullous disease of the skin and mucosa with 
genetic predisposition and autoimmune aetiology. HLA Class II genes are associated with 
pemphigus. IgG1 and IgG4 antibodies are the pathogenic antibodies in pemphigus of which IgG4 
is associated with active disease. The primary objective of this study was to find out the HLA 
DR and DQ types in pemphigus vulgaris in India, and to compare it to that in normal healthy 
controls.  Secondary objective was to look at the correlation between disease severity in terms of 
PDAI score and serum IgG4 levels.  
 
Methods: A hospital based cross-sectional study done over a period of 10 months. The diagnosis 
of pemphigus was established by clinical examination, biopsy, DIF and anti-Dsg ELISA. 
Pemphigus vulgaris patients were enrolled for HLA DR and DQ typing by PCR-SSOP method. 
Renal transplant donors were taken as controls. Clinical examination and PDAI score was done 
in pemphigus vulgaris and foliaceus patients with active disease and it was correlated with serum 
total IgG4 levels in them. Chi-square test was applied to analyze the frequencies of HLA DR and 
DQ types in cases versus controls. Spearman Rho was used to correlate serum IgG4 levels and 
PDAI scores. Mann-Whitney U test was used to look for the association between HLA types and 
disease severity. 
 
Results:  The study included 72 patients, 54 (75%) pemphigus vulgaris and 18 (25%) pemphigus 
foliaceus. Mean age at disease onset for pemphigus vulgaris patients was 39.2 ±13.3 years, M:F 
ratio 1:1.45. In pemphigus foliaceus group mean age at disease onset was 44.3 ± 12.9 years, M:F 
ratio 3.5:1.  The mean PDAI score was 23.5 in pemphigus vulgaris and 33.8 in foliaceus patients. 
Typical features on histopathology was seen in 88.4% pemphigus vulgaris cases and 100% 
foliaceus cases. DIF was positive in 91.4% vulgaris and 100% foliaceus cases. 
HLA typing was done in 50 patients and compared with 50 controls.  HLA DRB1*14 was 
present in 94% cases versus 36% controls (p<0.001).  HLA DQB1*05 was present in 94% cases 
versus 48% controls (p<0.001). The haplotype DRB1*14, DQB1*05 was present in 88% cases 
versus 28% controls (p<0.001).  Negative association was found with DRB1*15 (14% cases 
versus 32% controls, p<0.05) and DQB1*06 (16% cases versus 38% controls, p<0.05).  
 
HLA DQB1*03 was associated with more severe disease.  
Mean serum  IgG4 was 1114.4mg/L in pemphigus vulgaris patients and 1147.1mg/L in  foliaceus 
patients. Positive correlation between PDAI and IgG4 levels was present in pemphigus vulgaris 
patients, but did not reach significance levels.  This correlation was not observed in pemphigus 
foliaceus group. 
Key words: Pemphigus, PDAI, HLA DRB1, HLA DQB1, IgG4. 
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INTRODUCTION 
 
Pemphigus is a group of chronic  autoimmune bullous diseases that involves the skin and the 
mucosa. It has a worldwide prevalence varying from 0.76 to 5 per million.(1) The disease is 
more prevalent in India and Middle East than in Western Europe or North America.(2) 
Pemphigus is potentially fatal if left untreated. 
The pemphigus group is broadly divided into four types, pemphigus vulgaris, pemphigus 
foliaceus, paraneoplastic pemphigus and induced pemphigus. Common to all of the 
pemphigus group of disease is the formation of blisters within the epidermis due to 
destruction of the intercellular adhesion and separation of keratinocytes from one another  
that is known as  acantholysis.(3) 
The disease results from the interplay between genetic and environmental factors. Genetic 
susceptibility  to pemphigus  has been demonstrated by allele and haplotype studies from 
different parts of the world.(4) Individuals with certain human leukocyte antigen (HLA) 
allotypes  are predisposed to the disease, but the  susceptibility gene differs dependent on 
ethnic origin.(5) DRB1*14 and DQA1*01  and DQB1*05  have been found to be prevalent in 
patients from India  and in those of Indo–Asian descent whereas HLA DRB1*04 and 
DQB1*05  are most commonly found in the European population.(6) There is significant 
variation in the HLA allele types that have been reported in association with pemphigus from 
different ethnic population around the world. There is a paucity of data in this field from 
India,  this emphasizes the need to further study the  HLA types in pemphigus patients.    
Autoimmunity in pemphigus is characterized by the presence of antibodies to the intercellular 
adhesion molecules and other target antigens. Circulating and skin-fixed antibodies are 
present in all types of pemphigus.  Clinical and experimental evidence suggests the 
pathogenic role of these  antibodies in blister formation.(7) Studies have clearly demonstrated 
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that the  autoantibodies in pemphigus patients mainly belong to the IgG1 and IgG4 
subclasses.(7–11) IgG4 subtype is mainly thought to mediate acantholysis. In patients with 
active pemphigus vulgaris, IgG4 autoantibodies against desmogleins were found to 
predominate. 
  
3 
 
.  
AIMS AND OBJECTIVES  
 
Primary objective:  To study the prevalence of  HLA DR and DQ types in patients with 
pemphigus vulgaris and compare it to that in healthy  individuals without pemphigus.  
 
Secondary objective: To correlate the severity of disease in pemphigus vulgaris and 
pemphigus foliaceus patients having active disease as measured by Pemphigus Disease Area 
Index (PDAI) score with the serum levels of total IgG4. 
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REVIEW OF LITERATURE 
Pemphigus refers to a group of autoimmune blistering diseases involving the skin and 
mucous membranes. It is characterized histologically by intraepidermal bulla formation due 
to acantholysis and immunopathologically by the presence of in vivo bound and circulating 
immunoglobulins that are directed against the cell surface antigens and adhesion molecules  
on keratinocytes. The disease is potentially fatal if left untreated. 
History  
The word pemphigus is derived from the  greek word “pemphix” which means bubble.(1) 
Walter Lever in his monograph gave an account of the  first description of the disease. 
According to Lever  the first description of pemphigus in two patients was given by 
MacBride in 1777. Pemphigus foliaceus was identified as a distinct type by Cazenave in 
1844.  The classical description of acantholysis (loss of cell-cell adhesion) by Civatte,  in 
1943, led to the unambiguous differentiation of pemphigus from other subepidermal 
blistering diseases.  The modern history of pemphigus began in 1964 with the demonstration  
of circulating antibodies to keratinocyte surface antigens by Beutner and  Jordan. The 
discovery of these antibodies led to the understanding of autoimmune pathogenesis of 
pemphigus. Subsequently the antigenic targets were identified to be desmosomal cadherins. 
Desmoglein 1 (Dsg1) in pemphigus foliaceus and desmoglein 3 (Dsg3) protein in pemphigus 
vulgaris were eventually identified by immunohistochemistry.(12) 
 
Epidemiology 
 The worldwide prevalence of pemphigus varies from 0.76 to 5 cases per million per year and 
depends on the geographic area and ethnicity under study. A higher incidence of about 16 to 
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32 cases per million per year is seen in the Jewish race.(1)  People of Mediterranean descent 
and of the Middle East are also known to have a higher prevalence as compared to the 
Western population.(3) An average yearly increase of 11% was seen in a population based 
cohort study from UK. Younger age at onset is seen  in India and Middle East.(2) The age at  
presentation of disease  from other parts of the world  is the fifth decade.(13)  Children are 
rarely affected except in areas of  endemic pemphigus foliaceus. 
Pemphigus is known to affect males and females equally. However a recent internet-based 
survey of patients  found a female predominance.(14) 
 
Indian scenario  
In India the prevalence of pemphigus has been  reported  between 0.9 to 1.8%  in 
dermatology outpatient attendees.(15,16) An incidence of 4.4 cases per million was found on 
a clinic-based questionnaire survey in Thrisur, India.(17) Over fifty percent of pemphigus 
patients  were  under the age of 40 years at presentation.(18) Contrasting results have been 
seen with regard to gender ratio  from Indian studies with reports of male preponderance of 
3:1 to female preponderance of 1.2 :1.(15,18) Table 1 shows epidemiological data on 
pemphigus from different countries.  
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Table 1- Epidemiological data on pemphigus from different countries 
 
a  North America, Canada, Mexico. bquestionnaire based study, data collected via internet.  
  
Study  Region 
Duration of 
study 
Number of 
patients 
Age at onset 
in years 
Male :Female 
ratio 
Kanwar A J 
et al. (15) 
North India 1988-2004 328 39 1:1.2 
Kandan et 
al(19) 
South India 2006-2008 65 44.6 1:1.8 
Kim MR et 
al. (20) 
Korea 1993-2008 199 46.1 1: 1.1 
Chams-
Davatchi et 
al. (21) 
Iran 1984-2003 1209 42 1:1.5 
Ljubojevic et 
al. (22) 
 
Croatia 1980-1998 159 53 2:1 
Gupta VK et 
al. (14) 
Variousa 2011b 171 51.8 1:2.25 
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Etiopathogenesis 
Role of HLA antigens  
There is  convincing evidence to support the genetic basis for susceptibility to pemphigus. 
Pemphigus is an example of  polygenic disease that does not result from the Mendelian 
inheritance of single gene but from the  interaction of several different genes as explained by  
the concept of epistasis.(4) Since pemphigus is known to be an autoimmune disease due to 
loss of immune tolerance,  the candidate genes studied widely are the MHC class II genes 
which are important in regulating immunity. The  association of MHC class II genes with 
pemphigus has been reported for over 25 years.(4) 
 
 Major Histocompatibility Complex (MHC) or Human leukocyte antigens (HLA) as they are 
called in humans, span 4000 kbps on the  short arm of chromosome 6p21. The MHC consists 
of a linked set of genetic loci that encode many proteins that are involved in presenting 
antigens to the T-cells. They encode two distinct classes of cell surface molecules: class I and 
class II.  The class I molecules are expressed on the surfaces of virtually all nucleated cells at 
varying densities, while class II molecules are more restricted to cells of the immune system, 
primarily B lymphocytes and monocytes, and their expression on other cells is increased on 
stimulation by inflammatory cytokines. There are three different class I molecules namely 
HLA A, B, and C and  three class II molecules  DR, DQ, and DP.  Other genes that map at 
the MHC locus include those that encode a few complement components, TNF-alpha and 
lymphotoxin. These are called the MHC class III genes.(23) 
 
The HLA  genes exhibit a high degree of  polymorphism. The polymorphism for the Class II 
genes occurs due to change in nucleotide sequences coding for alpha-1 and beta -1 domains. 
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As a result of the polymorphism for a gene, variants of that gene are produced which are 
called alleles. The number of these alleles can be varied and over 280 alleles are known for 
the HLA DRB gene and 46 alleles are known for the DQB gene.(24) Since the alleles  are  
expressed in high frequency it is unlikely that the two alleles occupying the locus on 
homologous chromosomes in an individual will be the same.  The particular combination of 
alleles present on a HLA locus is called a haplotype. The expression of HLA alleles is co-
dominant. Codominance is the relation between two alleles of a gene wherein neither one is 
recessive, therefore the presence of one allele does not mask the expression of the other allele 
and both alleles of gene are expressed.(25) Polymorphism contributes to the wide diversity of  
HLA genes within individuals and populations. The polymorphism of HLA genes is of 
paramount importance in their function in presenting antigen.  
 
Class II molecules present antigens to T-cells and a T-cell that recognizes an antigen bound 
to one type of HLA will not recognize the same antigen when bound to another HLA allele. 
This specificity of antigen presentation and recognition is referred to as the MHC restriction 
of T-cells.(26,27) The HLA Class II molecule contains two transmembrane chains that are 
the alpha and beta chains (one for each locus) and each chain has two domain. The two distal 
domains form the peptide binding pocket by a non-covalent association between them. The 
different substitutions of  amino acids particularly in this peptide binding pocket determines 
the   variation of HLA alleles.(23) It is the variation in this peptide binding pocket that is an 
important determinant of antigen presentation and therefore responsible for the 
immunogenesis in pemphigus.(28) 
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The difference  between the peptide binding pocket of disease-associated HLA DR and DQ 
types in comparison with their normal types explains the structural basis by which specific 
HLA types confer susceptibility to pemphigus.  The presence of negatively charged amino 
acids in the beta-chain at the peptide binding site is responsible for the binding of 
desmogleins that are the main target antigens of pemphigus. This is in contrast to the  
molecules from the non-disease associated HLA gene sequences where the amino acids at the 
peptide binding site are positively charged. The negative charge of the peptide binding site 
confers selective binding to the desmoglein peptides which are positively charged. Thus 
amino acids that form the peptide binding residue are critical  for the presentation of peptides 
and they are determined by the mutagenesis of DRB1*0402 and DQ B1*0503.(28) 
 
Several conventional case-control studies have consistently identified DR4 and DR14alleles 
in association with pemphigus vulgaris in most parts of the world and DQB1 and DQA1 
alleles in certain other specific regions. The association of these different alleles  is seen with 
different frequencies in different ethnicities. The susceptibility genes of HLA DR4,  DR14 
and DQ types have also been found in pemphigus folicaeus, but as opposed to pemphigus 
vulgaris, no single allele is over expressed in the foliaceus patients.(29) 
 
Over 95% pemphigus patients have HLA DR4 or DR6 or both.(4) Of the DRB1 alleles nine 
subtypes (DRB1*0402, *0403, *0406, *1401, *1404, *1405, *1408, *0804,*0802) have been 
associated with pemphigus vulgaris  as reported from various studies over different 
population groups.(5)(30–33) (Table 2)  Of these DRB1 *0402 is more common in the 
European and American population while *1404 is more common in the Indo-Asian 
pemphigus patients.  DQB1*0302 and DQB1*0503  of the DQB alleles are also reported 
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worldwide in pemphigus vulgaris patients.  DQB1*0503 is more often associated with Indo-
Asian pemphigus patients  while DQB1*0302 is more frequent in European population.(6) 
Four alleles at the DQA1 locus,  DQA1*0101, *0104, *0401 and *0301 have been seen in 
pemphigus vulgaris of which the DQA1*0101 has also been found in pemphigus patients 
from India.(34) Negative correlation has been postulated with a handful alleles such as the 
DQB1*02 and  *06, DRB1*03, *13 and *17,  DQA1*0103.  Although no preventive benefit 
has been demonstrated with the possession of these alleles.(5,34) 
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Table 2-  HLA types  reported worldwide with pemphigus vulgaris 
Region/country 
No of 
patients 
HLA DR types 
HLA DQB 
types 
HLA DQA 
types 
Asia      
Indian(34) 37 1404, 0402 0503, 0302 0101 
Chinese(35) 27 0403,0406,1401,1404,1405 0503, 0302  
Japanese(36–
38) 
51, 32, 16 0406, 0802, 1401, 1405, 
1408 
0503, 0302 0104,0301 
Pakistani(39) 19 1404 0503 0101 
Middle East     
Iranian(40) 20 0402, 0302 0301 
Sardinian(41) 16 0402, 1401, 0503, 0302 0104, 0301 
Europe     
Jewish(33) 26 0402, 1401, 0302 - 
Italian (42) 87 0402, 0804, 1401, 1404 0503, 0302 0104, 0301, 
0401 
French (43) 37 0402, 1401, 1404 0503, 0302 - 
South American      
Spanish(44) 11 0402, 1401,  0503, 0302  
Argentinian(45) 47 0402,1401, 0503, 0302 - 
 
HLA DR B1*0402 is the most frequently associated allele in Ashkenazi Jews and Non-
Jewish Western population. Other alleles such as the DRB1*1401 and 1404 are reported from 
French, Italian, Japanese population. A meta-analysis of 18 case control studies representing 
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Asian, Caucasian and other nationalities indicated that DRB1*04, DRB1*08 and DRB1*14 
were associated with significant risk of pemphigus vulgaris. The meta-analysis did not 
include DR6 alleles.  As there was considerable heterogeneity in the DRB1*04 observed, 
ethnicity stratified test was done which showed reduced heterogeneity for Asians.  DRB1*08 
had an increased significance only for the Caucasian group. A protective role  was suggested 
by the negative correlation  reported with DRB1*03,  DRB1*07 and DRB1*15.(30) 
 
Of the DR6 alleles DQB1*0302 is consistently elevated in Jewish pemphigus vulgaris 
patients. DQB1*0503  is the other more widely associated allele of the DQB1 type in non-
Jewish population.(5) 
 
The DQA alleles that are associated with  pemphigus vulgaris patients include DQ A1* 0104 
and  DQ A1*0301. DQA1*0104 has been found in increased frequencies in Japanese 
pemphigus patients, while DQA1*0101 has been associated with pemphigus patients from 
India, Pakistan and Europe.(5,34,39,41) 
 
HLA allele types in  Indian patients  
Wilson et al’s study published in 1994 included 50  patients  of pemphigus from India and 20 
patients from UK. They reported  HLA DR1 and DR4 were increased in pemphigus patients 
of both countries.  DR1 (DRB1*01) was seen in 26% cases versus 14% controls among 
Indian patients and 26% cases versus 10% controls among  the patients from UK. DR4 
DRB1*04 was seen in 34% cases versus 26% controls in Indian patients, and in 47% cases 
versus 34% controls in  patients from UK.  They also reported a negative correlation of DR2 
(DRB1*15 or DRB1*16) in both the groups. Although the data regarding DR6 was not 
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presented, they mentioned it to be slightly higher in male patients as compared to female 
patients.(46) 
 
Delgado et al reported  HLA allele frequencies and haplotype analysis  of 39 pemphigus 
patients from India.(34) The study constituted of 2 subset of patients, one from New Delhi 
and the other from Ahmedabad.  The HLA alleles of the patient group was compared to 
haplotypes of healthy relatives. In this study they found HLA DRB1*1404, DRB3*0202, 
DQA1*0101, DQB1*0503 as the most prevalent alleles in patients as compared to that in 
controls. In addition to these they also identified a significantly higher prevalence for HLA 
DQB1*0302 among patients from Ahmedabad only.  Interestingly, HLA DRB1*0402 which 
has been the most frequently established association with pemphigus worldwide was found 
only occasionally in patients in this study and in association with DQB1*0302 that is similar 
to the haplotypes identified in Jewish population.  The study also identified DQB1*02 to be 
more prevalent in normal relatives than in the patient group, thereby  identifying it’s presence 
to have a protective effect for the development of pemphigus.(34) 
 
Saha et al’s study has laid further emphasis on the ethnic difference between pemphigus 
patients of the Indo-Asian population and the Western Europeans in the expression of HLA 
types.(6) The study included 96 Western-European patients and 57 Indo-Asian patients. The 
HLA type DRB1*1404 was the most significantly overexpressed allele in the Indo-Asian  
population as compared to  the Western-European, although DRB1*0402 was also reported 
from the Indo-Asians. The other alleles found to be significantly overexpressed were the DQ 
B1*0503 and DQB1*0302.  Since  DQB1*0503 and DQB1*0302 are frequently seen in 
association with DR14 and DR4 respectively they speculated that this association may be due 
to linkage disequilibrium and not a true predisposing factor for disease.(6) 
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Haplotype studies and sequence analysis of peptides of the predominant HLA types of 
pemphigus patients have been done to identify disease relevant alleles. The studies identified 
DRB1*0402 and  DQB1*0503  to be specific types that confer susceptibility to disease by 
their unique peptide pockets that can present desmoglein antigens. Whereas the other alleles 
such as DRB1*1401 and DQB1*0302 are overexpressed probably  due to linkage 
disequilibrium.(5) 
 
Other genes of the Major Histocompatibility Complex which have been studied for their 
involvement  in pemphigus include the Class III genes that encode Tumor necrosis factor-
alpha and lymphotoxin-alpha (LTA). Polymorphisms in TNF-alpha promoter gene is 
associated with susceptibility with pemphigus.(47) 
 
Role of non-HLA genes 
Non–HLA genetic targets  have also been explored in the causation of pemphigus. 
Pemphigus is characterized by autoantibodies of the IgG1 and IgG4 subclass with the latter 
being relevant in active stage of the disease.(48) Therefore the genes involved in type 
switching of the immunoglobulin gamma chain is a potential candidate gene for pemphigus. 
Various Th2 cytokines are involved in the antibody production and inflammation. Of these 
cytokines IL6 gene polymorphism  is the only one that showed significant difference in 
patients with pemphigus.(49) 
 
A recent study based on structural analysis of the anti-Dsg antibodies suggested that the 
antibody response is autoantigen derived.(48) This prompted investigators  to find out 
whether variations within locus of desmogein 3 and desmoglein 1 genes confer susceptibility 
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in pemphigus vulgaris and foliaceus respectively. The studies following this line of 
investigation found certain polymorphism markers for the desmoglein 1 and desmoglein 3 
genes in pemphigus foliaceus and pemphigus vulgaris respectively. But in both of these 
instances it was associated with the presence of HLA alleles that were known to confer 
susceptibility to pemphigus thus suggesting that they may have additive effects.(4,50) 
 
Role of Autoantibodies  
Autoantibodies of the IgG isotype are found in tissue and  the serum of patients with 
pemphigus. The primary role of anti-desmoglein antibodies in the pathophysiology of 
pemphigus is well established.(51) Evidence for this comes from in vitro and in vivo 
observations. Neonates born to mothers with active pemphigus develop transient pemphigus-
like disease due to transplacental transfer of antibodies. Pemphigus-like phenotype is induced 
in neonatal mice by the passive transfer of IgGs from patients with pemphigus.(52) 
 
The binding of antibodies to their targets i.e. desmogleins leads to acantholysis. This may be 
directly due to steric hindrance (direct hit theory) or indirectly by proteasomes and signal 
transduction. The ultrastructural studies of the antibodies demonstrated that pathogenic IgG 
antibodies bind specifically to particular ectodomains on the desmogleins at their amino 
terminal. The binding of the antibodies to desmogleins results in disassembly of the 
desmosomes.  The antigen – antibody complex are internalized thereby depleting the 
desmosomes at the intercellular space.(48,53) 
 
The anti-desmoglein antibodies in the serum can be detected either by indirect 
immunofluorescence (IIF) or enzyme-linked immunosorbent assays  (ELISA). Specific  
ELISA  using recombinant pemphigus antigens was developed by Ishii et al.(54) In their 
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study ELISA detected anti-Dsg3 antibodies in 46 /49 pemphigus vulgaris  patients and anti-
Dsg1 antibodies in 44/46 pemphigus foliaceus patients. None of the 53 controls showed 
positivity for the antibodies in this study. Thus they concluded the test to be sensitive and 
specific diagnostic tool for pemphigus. Amagai et al  found 97.9% of  pemphigus vulgaris  
patients had positivity for Dsg3 ELISA and 97.5% of pemphigus foliaceus patients has 
positivity for Dsg1 ELISA.(55) They also found that the Dsg antibody levels paralleled the 
course of disease.  They proposed  the Dsg ELISA be included as  diagnostic criteria for  
pemphigus since the presence of anti-Dsg1 and absence of anti-Dsg3 correlated with the  
pemphigus foliaceus, likewise presence of anti-Dsg3 and absence of  anti-Dsg1 correlated 
with mucosal pemphigus, and both antibodies were present in  mucocutaneous pemphigus. 
This finding was also supported by Schmidt et al (study on 71 vulgaris and 48 foliaceus 
patients)  and Daneshpazhooh et al (study on 73 pemphigus vulgaris patients).(56,57) 
 
Indian studies however did not concur with these results. The Dsg antibody levels did not   
correlate with the disease  phenotype. Khandpur et al in their study of 66 pemphigus patients 
and 77 controls found that  anti-Dsg1 and anti-Dsg3  antibody levels were elevated in both 
pemphigus vulgaris and foliaceus patients.(58) Anand et al reported that anti-Dsg3 titres were 
elevated in patients with cutaneous pemphigus and conversely anti-Dsg1 titres were elevated 
in patients of mucosal pemphigus vulgaris, therefore the  antibody titres did not  predict the 
clinical phenotype of pemphigus.(59) 
 
The anti-desmoglein antibody levels correlate   with severity of disease.  Kumar et al found 
that the anti-dsg3 and anti-dsg1 antibody levels determined the severity of oral and skin 
lesions in pemphigus patients. Their results was based on study of 44  pemphigus patients 
that included 38 vulgaris and 6 foliaceus patients.(60) 
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The IgG antibodies have been classified into four subclasses of antibodies designated G1, G2, 
G3 and G4 based in order of their normal serum concentrations. The subclasses differ in their 
heavy chains. IgG4 is the least common IgG in healthy individuals. It is also the most 
complex of them. Due to its unique structure it can act as a blocking antibody but does not 
form large immune complexes. It is not associated with complement activation.(61) 
 
The predominant antibody subclass seen in pemphigus are the IgG1 and IgG4.(8,9,62,63) 
Bhol et al, in a case control study done by them on pemphigus (study on 21 patients  with 
active disease, 18 patients in remission and 22 healthy controls),  described  the presence of 
IgG1 and IgG4 in high concentrations against a  specific peptide of the desmogleinin active 
disease, and IgG1 antibodies specific to  different peptide  in patients in remission and the 
controls.  This study highlighted the differences between the two subclasses of IgG antibodies 
in terms of epitope specificity and pathogenicity. The same group, using immunoblot 
technique,  also demonstrated  IgG1 and IgG4 antibodies in pemphigus patients with active 
disease while only IgG1 in patients in remission.(48) Several studies done thereafter have 
supported the pathogenic role of IgG4 antibodies.  IgG4 is found to be the predominant 
antibody in active  phase of the disease while IgG1 is seen in patients even during remission. 
The role of IgG subclasses in pemphigus was studied in a case control study model 
comparing the antibodies in patients to that in first-degree relatives of patients and in healthy 
unrelated individual. This study showed the presence of IgG4 in 62% of patients as compared 
to  6% in first degree relatives and was absent in healthy controls.(62) 
 
A case was reported of pemphigus vulgaris occurring in a  neonate,  born to a mother known 
to have pemphigus. The antibody subclasses as  tested by indirect immunofluorescence and 
ELISA  revealed the presence of higher titres of  IgG4 in both the mother and the neonate as 
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compared to the negative test for IgG1.(64) This report illustrates  the capacity of IgG4 
antibodies to induce acantholysis and blisters. Experimental studies done on mice with 
injection of IgG4 anitbodies developed against desmoglein3  produced acantholytic blisters 
on the mice skin.(52) 
 
IgG4 antibodies are probably responsible for the initiation of active disease. This is suggested 
by the observations that were made  in endemic pemphigus patients. In the regions endemic 
for pemphigus foliaceus  normal individuals were found to have IgG1 antibodies.  IgG1 was 
the predominant antibody in patients prior to onset of clinical disease. Whereas IgG4 
antibody titres were  high once  the  disease manifest clinically.(65) Dhandha et al in their 
study on immunoglobulin subtypes in pemphigus patients  emphasized the role of IgG4. They 
found that IgG4 was the sole subclass of antibody that correlated with clinical phenotype. 
The IgG4 anti-desmoglein 3 antibody was elevated in mucous predominant and 
mucocutaneous pemphigus and G4 anti-desmoglein 1 antibody was elevated in the cutaneous 
pemphigus, while this difference was not significant for other IgG isotypes. They also 
reported a  significant positive  correlation between disease duration and anti-Dsg3 IgG4 
antibody levels, an increase in the antibody levels was associated with longer disease 
duration. In this study it was also found that patients who were carriers of HLA gene types 
known to be associated with pemphigus  had higher IgG4 antibodies that those patients 
negative for the HLA types.(63) 
 
Role of environmental factors 
Environmental factors play a vital role in the pathogenesis of endemic pemphigus. The 
presence of the nigrimanum simulium fly  and other hematogenous insects in high frequency 
is associated with endemic pemphigus.(66) Several recent studies have implicated the role of 
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other environmental factors such as ingestion of certain food, contact with pesticides in the 
pathogenesis of pemphigus vulgaris. Foods and beverages such as garlic, berries, red wine 
and tea that are high in thiols, phenol and tannin compounds respectively may trigger the  
flares of disease activity. Occupational exposure to pesticides of the organophosphate group 
may induce pemphigus by inhibiting cholinergic receptors at the keratinocyte.(67) Hormonal 
factors have been implicated as a trigger for pemphigus, this is based on reports of pemphigus 
during pregnancy. Significantly higher oral contraceptive pills usage has  been associated 
with pemphigus, although the mechanism by which it acts as  trigger for pemphigus is still  
not known. Cigarette smoking on the other hand is said to have a protective role. This is 
explained by the immunosuppression caused by chronic nicotine exposure.(67) Drugs are a 
known causative factor for induced pemphigus. Drugs containing thiol group such as 
penicillamine and captopril can provoke blistering directly by their biochemical interference 
with cell-cell adhesion molecules, activating plasminogen and by altering the desmoglein 
antigenic structure and thus inducing antibody formation. On the other hand phenol 
containing drugs such as rifampicin and cephalosporins lead to release of interleukin and 
tumor necrosis factor from keratinocyte. These cytokines further lead to activation of  
plasminogen activators contributing to acantholysis.(68) 
 
Pathophysiology of  blister formation in pemphigus 
Desmosomes are intercellular bridges that attach two adjacent keratinocyte cell membranes. 
Desmosomes are composed of three groups of proteins namely (i) desmosomal cadherins, (ii) 
plakins and (iii) armadillo family proteins (plakophilins and plakoglobins). Of the cadherins 
the desmogleins are the main target in pemphigus.(69) Antibodies induce acantholysis by 
directly affecting desmoglein function. They interfere with cis-trans interactions (steric 
hindrance) and  bring about conformational change in the desmoglein ectodomain. 
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Antibodies indirectly inhibit desmoglein function by activating kinases such as the protein 
kinase C, plasminogen activator and p38 mitogen activated protein kinase (p38MAPK) that 
lead to desmoglein disassembly.(70) 
 
The basal cell shrinkage theory that has been put forth to explain acantholysis in pemphigus   
describes cytoskeletal collapse and keratinocyte cell volume reduction as the primary event in 
loss of adhesion of keratinocytes. The basal cell shrinkage may also be due to presence of 
antibodies to acetylcholine receptor on keratinocytes.(71)  Antibodies to several keratinocyte 
proteins have been found in pemphigus. Grando et al postulated that acantholysis is the end 
result of action of all these antibodies thus naming it the multiple hit theory.(72) The 
antibodies to acetylcholine receptor affects normal function of keratinocytes leading to 
rounding up of cells and loss of desmogleins. This is followed by stimulation of apoptotic 
pathways  and therefore the mechanism of blister formation has also been termed 
apoptolysis.(73) 
 
The clinical feature and differentiation of different types of pemphigus is determined by the 
distribution of desmogleins in epidermis and relative concentrations of specific antibodies to 
them as explained by the desmoglein compensation theory.(3) The theory is based on the 
assumption that antibodies to one isoform of desmoglein will inactivate only that specific 
isoform of desmoglein.   Desmoglein 1 is present throughout the epidermis of skin and 
weakly expressed in mucosa.  Whereas desmoglein 3 is present in lower part of epidermis 
and strongly expressed in the entire mucosal epithelium.  In pemphigus foliaceus antibodies 
are present against Dsg 1 thus blisters develop in the superficial layers of epidermis while the 
loss of Dsg1 in lower epidermis is compensated for by Dsg3. Similarly the mucosa is not 
affected because of the strong expression of desmoglein 3. On the other hand in case of 
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mucosal predominant pemphigus antibodies present against desmoglein 3 destroy it leading 
to erosions in oral mucosa. Mucosal erosions are the main manifestation in this situation 
since dsg1 is not adequately expressed in mucosa to compensate for the loss of Dsg3. The 
skin is not affected since Dsg 1 compensates for the loss of Dsg3 in lower epidermis.  In 
mucocutaneous type of pemphigus antibodies against desmoglein 1 are also present which 
explains the development of blisters on the skin.(29) 
 
Classification of pemphigus  
The pemphigus diseases are classified based on clinical features, the level of the split within 
the epidermis and the  antibody isotype that is predominantly seen on immunofluorescence 
studies. (Table 3) 
Table 3- Classification of pemphigus (29) 
Type of pemphigus Immunoglobulin type Antigenic target 
Pemphigus vulgaris  
Clinical Subtypes - 
Mucosal dominant  
Mucocutaneous 
 
Variant - 
Pemphigus vegetans 
 
 
 
IgG  
IgG 
 
 
IgG  
 
 
Dsg 3 
Dsg 1 + Dsg 3 
 
 
 
Dsg 1 + Dsg3 
Pemphigus foliaceus 
 
Variant  
IgG 
 
 
Dsg 1 
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 Pemphigus erythematosus  
Pemphigus herpetiformis 
IgG 
IgG  
Dsg 1 
Dsg 1 
 
Induced pemphigus  IgG  Heterogeneous  
Paraneoplastic pemphigus IgG  Dsg3, Dsg1, (Dsc),  
Plectin, desmoplakin, 
BP230, envoplakin, 
periplakin,  
 
IgA pemphigus  
Subtypes- 
SCPD type  
IEN type  
IgA pemphigus vulgaris 
IgA pemphigus foliaceus 
 
 
IgA 
IgA 
IgA 
IgA 
 
 
Desmocollin 1  
?unknown  
Dsg 3 
Dsg 1 
 
Endemic pemphigus 
Subtypes – 
Brazilian  
 
Tunisian  
Colombian  
 
 
IgG 
 
IgG 
IgG 
 
 
 
Dsg1, (Dsg3, ?Desmocollin1-
3) 
Dsg 1, Dsg 3 
Dsg 1 + α 
 
IEN – Intraepidermal neutrophilic IgA type, SCPD – subcorneal pustular dermatosis type  
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Clinical features of pemphigus vulgaris and foliaceus 
In most countries pemphigus vulgaris is more common than pemphigus foliaceus. The 
percentage of pemphigus vulgaris varies between 70 to 92percent of all cases. A few 
exceptions to this is seen in Tunisia and Finland where the ratio of pemphigus foliaceus is 
twice as common as pemphigus vulgaris.(3) 
 
Pemphigus vulgaris is the most common type of pemphigus seen  in  India. The percentage of 
pemphigus vulgaris  as reported by Indian studies ranges from 70% to 89% and that of 
pemphigus foliaceus from 3% to 20%.(18) Pemphigus vegetans, pemphigus erythematosus 
and paraneoplastic pemphigus are seen occasionally and together constitute about 5% of the 
pemphigus cases. It is a disease of 5th decade, however, in India over 50% of affected patients 
are below 40 years of age. Slight female predominance has been reported with M:F ratio of  
0.8:1, 1:1.48, and 1:1.82.(18,19,74) 
 
Pemphigus vulgaris and its variants  
Patients with pemphigus vulgaris present with mucosal erosions in 50 to 70% patients. (75) 
The disease may be confined to oral cavity in mucosal predominant subtype of pemphigus 
vulgaris. The oral lesions are often painful irregular erosions involving the most commonly 
the buccal and palatal region but the lips, the pharynx, the esophagus may also be involved. 
In patients who present with isolated oral lesions the diagnosis is often delayed. Other 
mucosae including the conjunctival, nasal, urethral, vulval and cervical can also be involved. 
Cervicovaginal erosions are present in 51% of women with pemphigus vulgaris.(75) 
Cutaneous lesions may be localized but more often are generalized. In the mucocutaneous 
type the mucosal lesions may precede the cutaneous involvement by an average of 5months 
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duration. The cutaneous lesions are  flaccid, thin-walled vesicles  and bullae on otherwise 
normal appearing skin. The blisters being fragile rupture easily leaving oozing erosions that 
have a tendency to extend peripherally. The sites predominantly involved are  flexural sites 
such as the axillae and the groin, the face and the scalp and sites prone to friction such as 
elbows. A characteristic sign can be elicited in pemphigus is the separation of normal-
appearing epidermis from the dermis by a firm sliding pressure. This sign known 
eponymously as Nikolsky’s sign is characteristic of active disease. The erosions heal with 
hyperpigmentation but without scarring. Nail involvement  presents as acute paronychia or 
rarely subungual hematoma.(2,75) 
 
Pemphigus vegetans is a variant of pemphigus vulgaris. Vegetating papillomatous plaques are 
seen especially in the intertriginous regions. Two subtypes have been described: Neuman 
type and the Hallopeau type. The Neuman type is more severe with the initial lesions being 
clear vesicles. The initial lesions in the mild Hallopeau type are pustules and the  vegetative 
plaques may be studded with pustules.(2) 
 
Pemphigus foliaceus and its variants 
Pemphigus foliaceus presents with scaly crusted erosions often on erythematous base. The 
lesions are generally well demarcated in early disease. The primary lesions that is superficial 
flaccid vesicle is usually not seen. The mucosa is not involved. Patients with pemphigus 
foliaceus may have disease limited mainly to the scalp and the seborrheic areas or may 
occasionally progress to erythroderma.(76) Pemphigus foliaceus affects middle-aged 
individuals. The data regarding gender ratio in pemphigus foliaceus is not available because 
there are few studies that have looked at pemphigus foliaceus alone. 
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Pemphigus erythematosus is a variant of pemphigus foliaceus. The characteristic feature is 
the presence of erythematous scaly lesions over the nose and cheeks, in  butterfly distribution 
of face. All patients with this variant have immunofluorescence pattern of pemphigus along 
with the presence of  IgG and complement in the basement membrane zone similar to the 
lupus band. Approximately 30% have positive antinuclear antibodies. However the 
development of lupus erythematosus in these patients is extremely rare and the disease course 
is similar to pemphigus foliaceus.(1,76) 
 
Pemphigus herpetiformis is an uncommon variant of pemphigus foliaceus. Itchy urticarial 
lesions with clusters of vesicles in herpetiform pattern are seen.  The histopathology in this 
condition rarely demonstrates acantholysis. The immunofluorescence is usually similar to 
pemphigus foliaceus. Rarely the herpetiform pemphigus may evolve into pemphigus 
vulgaris.(1,2) 
 
Induced pemphigus 
Induced pemphigus commonly presents in the clinical pattern of pemphigus foliaceus or 
erythematosus. Pemphigus vulgaris is rarely seen as a manifestion of  induced pemphigus. 
The ratio of induced foliaceus to induced vulgaris is approximately 4:1. Thiol –induced 
pemphigus resolves after withdrawal of the drug in 40-50% of patients, whereas among  the 
non-thiol induced pemphigus only 15% cases remit after drug withdrawal.(1) 
 
Assessing the severity of pemphigus 
Various scoring systems have been devised that can be used to assess clinical severity of 
pemphigus. The Pemphigus Disease Area  Index (PDAI) is one such scoring system. PDAI is 
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the result of a consensus of International Pemphigus Committee meetings in 2009  that were 
held to develop a tool to measure pemphigus disease activity. PDAI integrates cutaneous with 
mucosal disease in well-defined anatomical locations, assesses size and number of lesions 
and also scores the damage as seen by post inflammatory hyperpigmentation. Active lesions 
on skin and mucosae are each scored from 0 to 10 based on size and number of lesions and 
12 different anatomical sites are identified and  scored individually giving a maximum score 
of 120 each for skin and mucosa. The scalp region is scored separately with range of score 
from 0 to 10. Damage score is given as 1 point for presence of pigmentation for each of the 
12 anatomical regions on the skin and 1 for the scalp thus giving a maximum score of 13.   
The  total PDAI score  can  vary between 0 to 263.(77) 
 
Other scoring systems include the Autoimmune Bullous Skin Disorder Intensity Score 
(ABSIS), and Pemphigus Vulgaris Activity Score (PVAS).  ABSIS was developed by Pfutze 
et al and has been used widely in European studies. The score is calculated as sum total of 
skin scores, mucosal scores and objective score for oral intake as tolerated by the patient. The 
skin score can be a maximum of 150 points as given by assessing the extent and body surface 
area involvement which is weighted by the type of lesions. The mucosal involvement is given 
upto 11 points and the qualitative score given for oral discomfort can range from 0 to 45. The 
ABSIS score ranges from 0 to maximum of 206.(78) PVAS was introduced by Chams-
Davatchi et al. The score ranges from 0 to 18 and includes a point system scoring for extent 
of mucocutaneous involvement, the type of lesions and Nikolsky’s sign. The score is easy to 
use and was  found to correlate well with physicians global assessment.(79) Indian scoring 
systems that have been developed include the Kumar’s scoring system wherein  skin and 
mucosa are graded separately as no disease,  minimal disease, to severe disease giving a score 
of 0 to 3.(60) Saraswat et al presented a scoring system for oral pemphigus that took into 
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account extent  of involvement as an objective score ranging from 0 to 11 and a subjective 
score for severity based on patient’s discomfort. This score was similar to ABSIS with 
respect to inclusion of subjective discomfort of patient to oral diet, which was  scored from 0 
to 45.(78) In the  Mahajan’s scoring system for pemphigus, disease activity is  graded from 
mild to extensive based on body surface area involvement of skin, extent of oral involvement 
and the individuals functional impairment.(80) Harman’s grading of pemphigus ranges from 
0 to 3 each for the skin and mucosa based on the number of  erosions.(81) 
 
Rosenbach et al, in their study done to validate the PDAI score, have concluded it to be  more 
reproducible  and to correlate better with physician’s assessment of extent of disease in 
comparison to ABSIS score.(82) Ten dermatologists scored  15 pemphigus patients using 
both the PDAI and ABSIS scores. They also repeated the scoring assess reproducibility of the 
measurement tool.  The inter-rater reliability was the same for both scores, but PDAI had 
better reproducibility as seen on analyzing the re-test. The PDAI scores correlated better with 
physician global assessment. In a recent study done by Rahbar Z et al, PDAI was compared 
with ABSIS  as well as  PVAS. The study was done on 100 patients, they were rated 
individually  by 3 dermatologists for all three indexes PDAI, ABSIS and PVAS.(83) PDAI 
score was  found to have better inter-rater reliability and better correlation with desmoglein 
tires of patients. Thus the PDAI  has been consistently found to be a  superior  scoring system 
for the measurement of disease activity in pemphigus. 
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MATERIALS AND METHOD  
 
Study design 
The study was a  hospital based  cross-sectional  study  of patients with pemphigus  admitted 
in dermatology ward or attending the dermatology outpatient department.  
 
Setting  
The study was conducted in  the Department of Dermatology, Venereology and Leprosy at 
Christian Medical College,  a  tertiary  level hospital in Vellore, Tamil Nadu. 
 
Study duration  
The study was conducted between November 2013 and August 2014 (10 months).  
IRB approval 
The study was approved by the Institutional Review Board. (IRB approval no.8549) 
Inclusion criteria for cases  : 
1. Patients with pemphigus vulgaris diagnosed by clinical features,  histopathology and 
immunofluorescence or serological demonstration of anti-desmoglein antibodies and 
consenting for the study. 
2. Patients with pemphigus foliaceus diagnosed by clinical features, histopathology and 
immunofluorescence or serological demonstration of anti-desmoglein antibodies with 
active disease were included for studying the secondary objective i.e. correlation 
between PDAI score and IgG4 levels. 
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Exclusion criteria for cases : 
1.Patients not willing to participate in the study. 
2.Patients with paraneoplastic pemphigus. 
 
Inclusion criteria for Controls: 
1. Healthy renal transplant donors who were willing to participate in the study. 
 
Exclusion criteria for controls: 
1.Presence of autoimmune disease or immunobullous disease.  
2.Family history of immunobullous disease. 
 
Sample size calculation for  prevalence of HLA DR and DQ types in pemphigus vulgaris  
The sample size was calculated in the following way to show a difference in HLA allele 
of about 30% across patients and controls 80% of the time with 5% level of significance. 
The prevalence data used for the calculation of sample size was from the study by 
Delgado et al.(34) 
 n =  ( Z α/2 + Z 1-β ) 
2  X  2 X PQ   
                           d2 
 
P =(P1 + P2 )/ 2  
P = (48+17)/ 2 = 32.5 
 
Q= 100-32.5 +67.5% 
D = 48-17 = 30%  
 
Z α/2 = 1.96 (5% level of significance) 
Z 1-β = 0.84  (80% power) 
 
 
Where, P – prevalence from the literature  
             P1(48) = prevalence in cases 
P2(17)= prevalence in controls. 
 Q = 1-P 
 Z/2 is the standard normalized value at 5% level of significance 
 
The sample size calculated was 45 cases and 45 controls.  
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Methodology  
 
 Patients with established diagnosis of pemphigus vulgaris were enrolled in the study after 
informed consent was obtained by the principal investigator. 
 
The demographic details collected included the age, sex, area of residence.  History 
pertaining to the disease included the duration of disease, the anatomical site of onset of 
lesions,  the symptoms associated at the onset of lesions, the presence of photosensitivity, the 
history of drug intake that may have triggered the disease. Duration of disease in this study 
was the time duration from onset of symptoms till the inclusion in study. 
 
The details of treatment received by the patients was ascertained by scrutiny of previous 
records and when not available the history was relied upon and recorded. The total duration 
of steroid,   maximum dose of steroid received by the patient and the current dose were 
recorded. The details of other steroid sparing  immunosuppresants that the  patient  had been 
on, with the average  duration and dosage of each of the them were also recorded.  
 
History of associated comorbid conditions were recorded.  
In patients with active disease the skin, scalp and mucosae was examined. The type of lesions 
on skin  such as   vesicles, bullae, erosions,  vegetating plaques, acanthoma, post-
inflammatory macules and their distribution  were recorded.  The extent of oral mucosal 
involvement and the involvement of other mucosa such as the conjunctiva, nasal and 
anogenital was also recorded.  Nail involvement in the form of paronychia was noted.   
Nikolsky sign was performed in patients with active disease, as was bulla spread sign in 
patients with vesicular lesions.  
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The  severity of disease was objectively  assessed using  Pemphigus Disease Area Index 
(PDAI) (Annexure 2). Total   PDAI  score was calculated by sum of scores given  as per size 
of lesions and number of lesions present on the skin, mucosa and  scalp. Activity score was 
given for presence of erosions or bullae. It was calculated as sum of scores for 12 anatomical 
areas. The score in each area was given as 0, 1, 2, 3, 5 or 10.  The activity score for the scalp 
was given as 0, 1, 2, 3, 4 depending on the number of quadrants involved or as 10 if the entire 
scalp was involved. Damage score was given for each of the 12 skin areas and 1 for the scalp. 
Damage score of 1 was given for presence of hyperpigmentation or resolving erythema. 
Activity score for mucosal involvement was given as 0, 1, 2, 5 or 10 based on the number and 
size of  erosions or blisters  involving 12 sites.  The oral mucosa was given maximum 
weightage and constituted 8 of the 12 sites and the other 4 mucosal sites included eyes, nose, 
posterior pharynx and anogenital. Activity score for skin can range from 0 to 120, scalp score 
can range from 0 to 10,  damage score 0 to 13  and mucosal score ranged from 0 to 120. Thus 
the total PDAI can range from 0 to 263.  
 
Investigations  
Laboratory investigations included Tzanck smear from fresh erosion or early vesicle, skin 
biopsy  of early vesicular lesion if present,  direct immunofluorescence  of perilesional skin.   
Serum anti-desmoglein1 and anti-desmoglein 3 antibody  titres were done at the first visit  by 
ELISA.  
 
 
HLA DR and DQ typing 
HLA DR and DQ typing was done in pemphigus vulgaris patients. 
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Sample: 10mL blood sample was collected in an citrated tube by venepuncture of peripheral 
vein and DNA extracted by salting-out technique. 
The HLA DR and DQ typing was done by the Polymerase Chain Reaction Sequence Specific  
Oligonucleotide Probe  method using  Life Code SSO HLA typing kits with Luminex, 
product of Gen Probe Transplant Diagnostics Inc, Stamford, US. 
 
Principle of  PCR SSOP :  The selected DNA region for the specific genes to be detected is  
enriched by the polymerase chain reaction. Primers are used to generate excess of single 
stranded DNA material. Probes that are oligonucleotides homologous to specific sequences 
on the amplified DNA, i.e. the alleles that need to be identified,  are hybridized with the  PCR  
product. These probes are attached to microspheres that  can be identified by  their specific 
fluorescence. The fluorescence of multiple probes can be read at the same time. The resultant 
measurement of is given as positivity or negativity for a particular probe  for the amplified 
DNA sample. 
 
Serum total IgG4 
Serum total IgG4 levels were done in all patients with active disease at the time of 
recruitment in the study. 
Sample- 3-5 mL blood sample was collected by venepuncture of peripheral vein. Blood was 
allowed to clot and the serum separated as soon as possible to prevent haemolysis. The sera 
was then stored at 2-8⁰C. 
 
Serum IgG4 levels were measured by Nephelometry method using the MININEPH Human 
IgG4 kit, a product of  The Binding Site Group Ltd, Birmingham, UK. 
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 Principle of  nephelometry :   The amount of light that is scattered by a solution 
depends on the amount of particles that are suspended in it. The IgG4  are protein molecules 
that are soluble in the serum.  Addition of antibodies  to them makes them form small 
antigen-antibody complexes  that remain in suspension . The amount of light that is scattered 
will be directly proportional to the concentration of the IgG4 in the sample. This amount of 
scattered light is then measured and compared with the light scattered  from known solutions 
as given by a standard calibration curve.  
The normal serum IgG4 levels in adults ranges from  62  to 1127 mg/L.  
 
Statistical analysis   
The data was  entered in Epidata version 3.1, and analyzed using the software SPSS version 
17. Continuous variables were analyzed and represented by using mean and standard 
deviations.  Categorical variables like gender, type of pemphigus were described using 
frequencies with percentages.   
 
The HLA allele frequencies in cases and controls were compared using the Chi-square test.   
Spearman Rho   correlation coefficient was used to correlate PDAI scores with serum total 
IgG4 levels, PDAI scores with anti-desmoglein titres and IgG4 with  anti- desmoglein titres. 
It was diagrammatically represented on scatter plots. 
The Mann-Whitney U test for used  to analyse the relation of HLA DR and DQ types with   
disease severity. 
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RESULTS 
 
Seventy-seven patients  with pemphigus were  seen during the period of study from 
November 2013 to August 2014. The diagnosis was not confirmed in  3 clinically suspected 
pemphigus cases. This was due to failure to follow up for investigations. One patient was 
diagnosed to have paraneoplastic pemphigus therefore excluded from study.  One patient was 
not willing to participate in the study.   Seventy two patients consented to participate in the 
study. Of the 72 patients, 30  were newly diagnosed cases. The proportion of patients with 
pemphigus  among new dermatology attendees during the study period was 0.5%  (30 / 5796 
patients). 
 
Fifty-four (75%)  patients had  pemphigus vulgaris (75%) of whom 3 patients had pemphigus 
vegetans and 18 (25%)  patients had  pemphigus foliaceus.   
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74 patients presented with pemphigus 
during the study period 
72 patients met 
inclusion criteria  
2 patients were 
excluded (1- not 
willing to participate 
in study, 2nd-
paraneoplastic 
pemphigus) 
54 pemphigus vulgaris 
patients  
18 pemphigus foliaceus 
patients 
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Demographic profile of patients  
The mean age at presentation of patients with pemphigus was 43.19± 14.06 years (range, 12 -
70 years). There were 36 (50%) females and 36 (50%)  males (M;F ratio 1:1). The frequency 
distribution of patients in different age groups with gender is given in figure 1.  Thirty 
percent  of  the patients   were in the age group of 41 -50 years.   
 
The mean  age at onset of disease in  patients with pemphigus vulgaris was 39.25  ± 13.33 
years (range, 12- 68 years).  In 26 patients (48.1%)  the onset of disease was before the age of 
40 years and in 4 of them the age at onset was 20 years or less.  
 
Among the pemphigus vulgaris patients there was slight female predominance, 32 females 
and 22 males (M:F ratio was  1:1.45). 
 
In the patients with pemphigus foliaceus the age at onset was higher, mean age of 44.36 years 
±12.9  (range, 24 - 66 years). However in the   pemphigus foliaceus group of  patients  there 
was a high proportion of males compared to females with M:F ratio of    3.5:1.  
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Figure 1: Age and sex distribution of pemphigus patients 
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Majority of the patients were from Tamil Nadu (n=25), followed in frequency by West 
Bengal (n=19), Andhra Pradesh (n=8) and 3 patients each from Kerala, Bihar, Jharkhand, 
Chhatisgarh and the remaining 8  patients were  from different states of the  North-East India.  
The geographical distribution of patients is as represented in figure 2.  
 
 
 
 
Figure 2:  Georgraphical distribution of 
pemphigus patients  
Tamil nadu West bengal Andhra Pradesh Kerala
Bihar Jharkhand Chhatisgarh North East India
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Clinical profile of patients : 
Site of involvement : 
The oral mucosa was the first site of onset of disease in 44 (81.6%)  of the pemphigus  
vulgaris patients,  the skin and scalp were the first site to be involved in 5 (9.2%) patients 
each as represented in figure 3.  Among the pemphigus foliaceus patients skin was the  first 
site of onset of disease in 12/18 (66.7%), in the   remaining  6/18 (33.3%) patients the disease 
first  began on  the scalp. 
 
 
 
 
 
44
7
1.40
Figure 3: Diagrammatic representation of site 
of onset of disease in pemphigus vulgaris 
oral mucosa skin scalp
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Duration of disease prior to inclusion into the study 
The duration of disease prior to inclusion in the study ranged from 2 months to 15 years with 
median duration of 2.5 years.  The duration of disease in pemphigus vulgaris patients was  
2.9 ± 2.7 years and in pemphigus foliaceus was 2.4 ± 1.9 years.   
  
Associated symptoms  
Pain was  the most common symptom at presentation at disease onset, among patients with 
pemphigus vulgaris (48.1%) whereas pruritus was the most common symptom in patients 
with pemphigus foliaceus (57.9%). The frequency of  presenting symptom  in pemphigus 
vulgaris and foliaceus patients is given in table 4.  
 
Table 4-Associated clinical symptoms in patients with pemphigus vulgaris and 
pemphigus foliaceus 
Symptom 
Number  of patients (percentage) 
Pemphigus vulgaris (n=54) Pemphigus foliaceus (n=18) 
Pain  26 (48.1%) 2 (11.1%) 
 
Burning  8 (14.8%) 1 (5.5%) 
 
Itching  5 (9.3%) 11 (61.1%) 
 
Pain and burning  5 (9.3%) 0 
 
Pain and itching  7 (12.9%) 1 (5.5%) 
 
No symptom 3 (5.6%) 3 (16.6%) 
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History of photosensitivity was elicited in 6 out of the 54 pemphigus vulgaris patients and 3 
of the 18  pemphigus foliaceus patients. 
 
Drug inducing pemphigus 
The history of drugs triggering pemphigus was obtained in one patient of pemphigus vulgaris 
and the probable drug implicated was angiotensin convertase  inhibitor enalapril.   
 
Prior treatment  of pemphigus 
Majority of the pemphigus  patients (n=68, 94.4%)  in our study had been on treatment with 
specific therapy prior to their inclusion in this study and all of them were being treated with 
steroid with or without other immunosuppresants. The steroid-sparing immunosuppressants 
used included azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate and 
dapsone. One patient of pemphigus vulgaris  had received IVIG in the past. Azathioprine was 
the most frequently (50.7%)  used steroid sparing agent.   
 
The frequency distribution of the immunosuppressants used and their average duration of use  
is given in table 5.   
 
Of the 68 patients who were on  steroid therapy 54 had received only oral steroid, 12  had 
received pulse steroid with cyclophosphamide in the past, 1 patient each  received oral and 
intravenous steroids  and 1 patient had received oral and intramuscular steroids.  The 
maximum dose of oral steroid  used to treat patients ranged from 0.2 – 1.75mg/kg,  with 
average  dose of  0.9mg/kg (± 0.36mg/kg).   
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Table 5-  Steroid-sparing immunosuppressants used in patients prior to inclusion in 
study  
Immunosuppresant /adjuvant 
used 
 
Number of patients 
(percentage) 
Average duration of 
treatment in years 
(range) 
Azathioprine  
 
37  (50.6%) 1.22 (0.03-5 ) 
Cyclophosphamide  
 
13  (17.8%) 0.85 (0.02 -5) 
Mycophenolate mofetil 
 
2  (2.7%) 0.41 (0.08-0.75) 
Methotrexate  
 
5  (6.8%) 0.84 (0.08-2) 
Dapsone 
 
11  (15.0%) 0.82 (0.08- 4) 
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Associated comorbid  conditions 
 
Fifty two of the 72 patients (72.2 %) had other associated  comorbidities of which vitamin D 
deficiency was the most common (n=27, 35.5%), followed in frequency by diabetes mellitus 
seen in  (n=24,  33.3%).  Hypertension was  present in 18 patients (25%), hypothyroidism 
was seen in 3 patients (4.2%), osteoporosis and  osteopenia was seen in 7 patients (9.7%). 
HIV and HCV was positive in one patient each,  and bronchial asthma, atopy,  adjustment 
disorder, and  past history of tuberculosis were seen in one patient each. (Figure 4) A single 
patient had retroperitoneal fibrosis and presented with clinical and DIF features of pemphigus 
vulgaris. Subsequently, six months later she was diagnosed to have non-Hodgkin’s 
lymphoma.   
 
 
0 5 10 15 20 25 30
Adjustment disorder
Tuberculosis
HCV
HIV
Bronchial asthma
Atopy
Retroperitoenal fibrosis
Non Hodgkin's lymphoma
Hypothyroidism
Osteopenia and osteoporosis
Hypertension
Diabetes mellitus
Vitamin D deficiency
Figure 4: Bar chart representation of the frequency of 
comorbid conditions in patients with pemphigus
number of patients
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Family history of  pemphigus 
Family history of pemphigus was not present in any patient.  
Clinical profile  
Of the 54 patients of  pemphigus vulgaris, disease was active in 42 patients and 10 patients 
were in remission. In patients with active disease, the oral mucosa was the most common site 
of involvement in patients with pemphigus vulgaris (35/42, 83.3%) Other mucosal 
involvement was present in 7 patients (16.6%), 5 patients had genital mucosal involvement 
(11.9%), 1 patient each had eye and nasal mucosal involvement.  Flexural involvement was 
seen in 10 patients (23.8%). Paronychial involvement was seen in 7 patients (16.6%). 
Nikolsky sign was positive in  6 of the  33 (18.8%)  pemphigus vulgaris patients in whom 
skin lesions were present. Majority of patients had mucocutaneous type of pemphigus 
(92.56%), 3 patients had mucosal pemphigus (5.56%) and 1 patient had cutaneous type of 
pemphigus vulgaris (1.8%). (Figure 5) 
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Figure  5:  Clinical   types  of  pemphigus  
vulgaris  
mucocutaneous pemphigus mucosal predominant  pemphigus
cutaneous pemphigus vulgaris
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Of the 18 pemphigus foliaceus patients skin lesions were present in  all the patients and scalp 
was involved in 13 cases and one patient had paronychial involvement.   One patient of 
pemphigus foliaceus was in erythroderma. Nikolsky sign was positive in 9  patients (50%).  
The frequency of distribution of skin lesions in  both the groups is detailed in table 6. 
Table 6- Distribution of lesions   in pemphigus patients in this study 
 
Site involved 
Number of pemphigus vulgaris 
patients  (percentage) 
Number of  pemphigus 
foliaceus patients 
(percentage) 
 
Skin  
  
Face  20 (47.6) 13 (72.2) 
Upper limbs  21 (50.0) 17 (94.4) 
Lower limbs  16 (38.0) 9 (50.0) 
Trunk  31 (73.8) 17 (94.4) 
Fexures 11 (26.1) 6 (33.3) 
 
Mucosa  
Oral 
 
 
35 (83.3) 
 
- 
Eye 1 (2.3) - 
Nasal 1 (2.3) - 
Genital  5 (11.9) - 
 
Scalp  
 
20 (47.6) 
 
13 (72.2) 
 
Nails  
 
 
7 (16.6) 
 
1 (5.5) 
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PDAI score 
The mean PDAI score in pemphigus vulgaris patients was  24.1 with the minimum score of 1 
and maximum score of 75. In  the pemphigus foliaceus patients the PDAI score ranged from 
minimum of 3 to maximum of 105 with an mean score of 34.73.   
 
 
Table 7-The mean PDAI score of pemphigus vulgaris and foliaceus patients 
Parameter 
Mean score (SD) in pemphigus 
vulgaris patients (n=42) 
Mean score(SD) in pemphigus 
foliaceus patients (n=18) 
Activity score of skin  
(range, 0-120) 
9.83   (±14.01) 26.17 (±29.48)  
Damage score 
(range, 0-13) 
3.28  (±2.97) 4.11 (± 3.14)  
Activity score scalp 
(range, 0- 10) 
1.57 (±2.17) 3.61 (±3.98)  
Mucosal score 
(range, 0-120) 
8.88 (±13.03) Not involved 
Total PDAI score 
( range, 0- 263) 
23.57 (±23.20)  33.83 (±30.24) 
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Investigations  
 
Tzanck smear was positive for acantholytic cells in 19 patients in pemphigus vulgaris and 10 
patients of pemphigus foliaceus. It was negative in 6 patients of pemphigus vulgaris and 4 
patients of pemphigus foliaceus.   
 
Antinuclear antibodies (ANA) was done in 3 out of 6 of the pemphigus vulgaris patients  and 
2 out of 3 of the  pemphigus foliaceus  patients who had  history of photosensitivity. ANA 
was negative in all of   5 cases.     
 
Biopsy was done at the time of diagnosis in 43/ 54 pemphigus vulgaris patients, of  which 38 
cases (88.4%)  showed typical suprabasal bulla with acantholytic cells. In 5 patients  the 
histopathology was not characteristic of pemphigus vulgaris. In these 4/5  cases the diagnosis 
was established by positive direct immunofluorescence and acantholytic cells on  Tzanck 
smear  and in the remaining case  with high titres of  anti-desmoglein antibodies.    In the 
remaining cases where biopsy was not done, the diagnosis was either confirmed elsewhere 
prior to the patients visit to our hospital or  by  direct immunofluorescence and ELISA anti-
desmoglein antibodies. Direct immunofluorescence of perilesional skin was done in 47/54 
patients (87%). Of these 47, DIF was positive in 43/47 (91.4%) cases,  in 42 cases (89.3%)  
intraepidermal immunoglobulin G was present, in 33 cases (70.2%) complement (C3) was 
also present. In one case IgG was negative but C3 was present. The most common pattern of 
IgG was  intercellular deposit of  lower one third of epidermis  and IgG was negative in 5 
cases. IgG was deposited along basement membrane in one case of pemphigus vulgaris, but 
the clinical features were suggestive of pemphigus vulgaris and there was no evidence of 
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associated malignancy. Complement (C3) deposit was   more often located in the lower third 
of the epidermis. Complement deposit was not seen in 14 cases. (Table 8) 
 
 In the pemphigus foliaceus group of patients, biopsy was contributory to diagnosis in all 12 
patients in whom biopsy was done.  Direct immunofluorescence was positive for 
intraepidermal IgG in all  the 18 pemphigus foliaceus patients. IgG deposits were present in 
entire thickness of the epidermis in 12 cases (66.6%)  and  in the lower half of the epidermis 
in  6 cases (44.4%).  Complement deposit was present in  lower third of the epidermis  in 8  
patients (44.4 %) and the entire thickness of  epidermis in 7 cases (38.8%).  (Table 9) 
 
A summary of the direct immunofluorescence findings in our study in given in table 10.  
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Table 8-Diagnostic investigations done in patients with pemphigus vulgaris 
 
Study 
number 
 
Tzanck smear Biopsy 
IgG 
deposit 
on DIF 
Complement 
deposit on 
DIF 
Serum Anti-
Dsg1 
in u/mL 
(normal  
2-20u/mL) 
Serum 
Anti-Dsg3 
in u/mL 
(normal  
2-20u/mL) 
1 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present 
 
Present 210 156 
2 
Negative 
 
Pemphigus 
vulgaris 
Present 
 
Present 147 173 
3 Negative Not done Not done Not done 135 161 
4 Not done 
Pemphigus 
vulgaris 
Present 
 
Absent 
 
85 155 
5 
Negative 
 
Pemphigus 
vulgaris 
Present 
 
Present 
 
2 122 
6 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present 
 
Present 13 160 
7 Not done 
Pemphigus 
vulgaris 
Present 
 
Present 6.3 7.1 
8 Not done 
Not 
characteristic 
Not done Not done 49 143 
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9 Not done Not done Not done Not done 7.6 170 
10 Not done Not done Not done Not done 5.5 211 
11 Not done 
Not 
characteristic 
Present Absent 43 202 
12 Not done 
Pemphigus 
vulgaris 
Present Present 12.2 176 
13 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Absent 2 2 
14 Not done Not done Not done Not done 15.2 122 
15 Not done 
Pemphigus 
vulgaris 
Present Present 1.5 99 
16 
Acantholytic 
cells 
Not done Absent Absent 8 166 
17 Not done 
Pemphigus 
vulgaris 
Present Absent 182 185 
18 Not done 
Pemphigus 
vulgaris 
Present Absent 2 67.4 
19 Not done 
Pemphigus 
vulgaris 
Present Present 2 143 
20 Not done Not done Present Absent 4.5 187 
21 Not done 
Pemphigus 
vulgaris 
Present Present 190 202 
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22 Not done 
Pemphigus 
vulgaris 
Present Present 15 4.2 
23 Not done Not done Present Present Not done Not done 
24 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Absent Absent 3.8 4.8 
25 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 148 169 
26 
Acantholytic 
cells 
Not 
characteristic 
Present Present 2.3 195 
27 
Acantholytic 
cells 
Not 
characteristic 
Present Absent 2 16.4 
28 Negative 
Pemphigus 
vulgaris 
Present Present 72 144 
29 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 2 14 
30 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 31.3 194 
31 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 256 200 
32 Not done 
Pemphigus 
vulgaris 
Present Present Not done Not done 
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33 Negative 
Pemphigus 
vulgaris 
Present Absent 5.6 79 
34 Negative 
Pemphigus 
vulgaris 
Present Present 161 144 
35 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Absent 29 198 
36 Not done 
Pemphigus 
vulgaris 
Absent Present 2 66 
37 Not done 
Pemphigus 
vulgaris 
Present Present 260 252 
38 Not done Not  done Present Present 2.2 249 
39 Not done 
Pemphigus 
vulgaris 
Present Present 2 2 
40 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 2 11 
41 Not done 
Pemphigus 
vulgaris 
Absent Absent 68.5 76.3 
42 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 14.7 243 
43 Not done 
Pemphigus 
vulgaris 
Negative Absent 151 121 
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44 Not done 
Pemphigus 
vulgaris 
Present Present 3.06 248 
45 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 9.2 257 
46 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 180 256 
47 
Acantholytic 
cells 
Not 
characteristic 
Present Absent 66 250 
48 Negative Not done Present Present 127 261 
49 Negative 
Pemphigus 
vulgaris 
Present Present 37 221 
50 Not done Not done Not done Not done 51 249 
51 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present 267 250 
52 
Acantholytic 
cells 
Pemphigus 
vulgaris 
Present Present NA NA 
53 Not done 
Pemphigus 
vulgaris 
Not done Not done 2 19.4 
54 Not done Not done Present Present 5.3 94 
  
*In patients with long standing disease where the diagnosis was established previously and 
the patient were on treatment Tzanck, biopsy and/or DIF were not repeated in our study. The 
anti-desmoglein levels  contributed to the diagnosis and served as a measure for disease 
activity assessment  in these cases. 
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Table 9- Diagnostic investigations done in patients with pemphigus foliaceus 
Stud
y no 
Tzanck test Biopsy 
IgG 
deposit 
on DIF 
Complement 
deposit on DIF 
Serum 
Anti-Dsg1 
(Normal= 
2-20u/mL) 
Serum 
Anti-Dsg3 
(Normal= 
2-20u/mL) 
1 
Acantholytic 
cells 
Pemphigus 
foliaceus 
Present Present 146 2 
2 
Acantholytic 
cells 
Pemphigus 
foliaceus 
Present Absent 200 2 
3 
Acantholytic 
cells 
Not done Present Present 166 86 
4 
Negative 
 
Not done 
 
Present Absent 163 2.1 
5 
Acantholytic 
Cells 
Not done Present Present 234 117 
6 Negative 
Pemphigus 
foliaceus 
 
Present Present 26.4 2 
7 
Negative 
 
Notdone 
 
Present Present 223 163 
8 Negative 
Pemphigus 
foliaceus 
 
Present Present 291 2.2 
9 Not done 
Pemphigus 
foliaceus 
 
Present Present 130 2.5 
10 
Acantholytic 
cells 
Pemphigus 
foliaceus 
 
Present Present 204 32 
11 
Acantholytic 
cells 
Pemphigus 
foliaceus 
 
Present Present 150 29 
12 
Acantholytic 
cells 
Not done Present Present 234 94 
12 
Acantholytic 
cells 
Pemphigus 
foliaceus 
 
Present Present 242 2 
14 Not done 
Pemphigus 
foliaceus 
 
Present Absent 136 2 
15 
Acantholytic 
cells 
Not done Present Present 231 0 
16 Negative 
Pemphigus 
foliaceus 
 
Present Present 1 1 
17 
Acantholytic 
cells 
Pemphigus 
foliaceus 
Present Present 234 33 
18 Not done 
Pemphigus 
foliaceus 
Present Present 
Not 
available 
Not 
available 
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Table 10-Summary of Direct Immunofluorescence findings in  pemphigus patients  
 
Immunodeposit on DIF 
 
Pemphigus vulgaris, n=47 
(%) 
 
Pemphigus folicaeus, n=18 
(%) 
IgG 
 
  
Lower one third  25 (53.2)) 0 
Lower half of epidermis 12 (25.5) 6 (33.3) 
Entire epidermal thickness  4 (8.5) 12 (66.6) 
Basement membrane 1 (2.1) 0 
Total positive  42 (89.3) 18 (100) 
Negative  
 
4 (14.8) 0 
   
Complement C3 
 
  
Lower epidermis  20 (42.6) 8 (44.4) 
Entire epidermal thickness  0 7 (38.8) 
Basal cells  13 (27.6) 0 
Total positive 33 (70.2) 15 (83.3) 
Negative  14 (29.7) 3 (16.6) 
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In the pemphigus vulgaris patients, serum desmoglein antibody levels were available for 52 
patients, the mean (SD) anti-Dsg3 antibody titres was 147.01 (±82.80) u/mL.  The anti-Dsg3 
titres ranged from 2u/mL   in patients in remission to maximum of 257 u/mL in patient with 
active disease. The mean anti–desmoglein1 antibody level was 60.8 u/ mL. 
 
The mean (SD) anti-desmoglein 1 antibody level in pemphigus foliaceus patients was  177.14 
(±78.22) u/mL. Anti-desmoglein 1 antibody level ranged from  1 to 291 u/mL. 
 
Correlation between anti-desmoglein 1 and PDAI in foliaceus patients showed a significant 
positive correlation. (R=0.54, p=0.02) as represented in the scatter plot in figure 6. 
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Figure  6: Correlation of anti-Dsg 1 levels with 
PDAI scores in pemphigus foliaceus
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Correlation between anti- desmoglein 3 and PDAI in pemphigus vulgaris patients showed a 
strongly significant positive correlation. (R=0.52, p=0.0004) as seen in scattered plot below 
in figure 7. 
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Figure 7: Correlation of anti-Dsg 3 with PDAI in 
pemphigus vulgaris  
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HLA types in  the   pemphigus  vulgaris  patients 
 
The required sample size (45) was achieved,  we enrolled 50 cases of pemphigus vulgaris and 
50 controls. Controls were taken from renal transplant donors. The mean age was 36 years 
(range, 19-57 years). There were 36 males and 14 females. 
 Forty-seven out of the 50 cases (94%) of pemphigus vulgaris had at least one HLA 
DRB1*14   allele, and 9 cases (18%) were homozygous for the allele. Among the controls 
HLA DRB1 *14 was present as at least one of the alleles in 18 controls (36%) and one was 
homozygous for DRB1*14.  When compared with controls the difference in frequency of 
HLA DRB1*14 was found to be significant (p <0.001).  On the other hand HLA DRB1*15 
was present in 15 of the controls and 5 controls were homozygous for DRB1*15, and  it was 
present in 7/50 cases. The difference in frequency of DRB1*15 was significantly high in 
controls (p =0.04). Nine controls were positive for DRB1*11, while only 2/50 patients were 
positive for it, resulting in significantly higher frequency of DRB1*11 in controls (p <0.05).  
The other DRB1 alleles that we found in our pemphigus patients were DRB1*03, DRB1*04, 
DRB1*07, DRB1*08, DRB1*10,  DRB1*12, DRB1*13,  and  DRB1*16.  The frequency of 
the different HLA DRB1 alleles found in this study  are given in table 11. 
 
 Of the HLA DQB alleles, DQB1 *05 was  seen in 47/50 patients (94%)  and   in 24/50 
controls (48%) (p < 0.001). Ten cases (10/47) were homozygous for HLA DQB1*05.  HLA 
DQB1*06 was found to be more common in the control population (18/50) than the  patient 
group (8/50 cases) (p = 0.02). The other HLA DQB types that were seen in our patients with 
pemphigus were DQB1*02, DQB1*03, and DQB1*04.  The frequency of HLA DQB1 alleles 
in patient and control group is given in table 12.  
 
60 
 
Haplotype analysis revealed a high frequency  of the haplotype HLA DRB1*14,DQB1*05  
among  the pemphigus patients (44 of 50,  88%), of these 7 patients were homozygous. 
Among controls the haplotype DRB1*14, DQB1*05 was seen in 14/50. This difference in 
frequency of this haplotype in cases versus controls was significant with p <0.001.  The 
haplotype DRB1*04, DQB1*03 was present in 12/50 cases (24%), none being homozygous 
for it. Among the controls 6/50 had the DRB1*04, DQB1*03 haplotype. The difference in 
frequency between the two groups was not statistically significant.  We also found that 
haplotype DRB1*15, DQB1*06 was significantly more common in the control population. 
(Table 13) 
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Table11- HLA DRB1 alleles in  pemphigus vulgaris patients as compared to healthy 
controls 
DRB1 alleles 
 
Pemphigus 
vulgaris(n=50) 
 
Controls ( n=50) P value 
*01 0 3 0.08 
*03 1 2 0.56 
*04 13 8 0.24 
*07 8 14 0.17 
*08 4 1 0.17 
*09 0 1 0.31 
*10 2 5 0.24 
*11 2 9 0.02 
*12 3 10 0.045 
*13 2 6 0.149 
*14 47 18 <0.001 
*15 7 16 0.03 
*16 1 0 0.316 
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Table 12- HLA DQB1 allele frequency distribution in pemphigus patients versus 
controls  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13-  Comparison of haplotypes between pemphigus patients and healthy controls  
 
 
  
DQB1 
alleles 
 
Pemphigus 
vulgaris (n=50) 
 
Controls  
(n=50) 
 
P value 
 
 
*02 4 11 0.05 
*03 24 25 0.55 
*04 3 1 0.31 
*05 47 24 <0.001 
*06 8 19 0.02 
Haplotype 
 
Pemphigus 
patients 
 
Controls 
 
P value 
 
DRB1*14/DBB1*05 
 
44 
 
14 
 
<0.001 
 
DRB1*04/DQB1*03 
 
12 
 
6 
 
0.138 
 
DRB1*15/DQB1*06 
 
5 
 
15 
 
0.018 
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As represented in the bar chart (figure 8) the allele types and haplotypes were distributed 
evenly in  males and females. (There was no statistically significant difference based on 
gender). 
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Figure 8: Gender wise distribution of HLA alleles and 
haplotypes
males females
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CORRELATION OF  HLA  TYPES WITH  DISEASE  SEVERITY  
 
 
The presence of HLA DQB1*03 (in 17/40 cases)  was associated with significantly  higher 
PDAI scores (mean score =  33.8) as compared to that of patients with absence of the allele 
(23/40 cases, mean PDAI = 16.6)  with  p value of 0.025. 
 
The disease severity could not be compared in those with the presence of  the allele and those 
in whom it was absent in case of HLA DRB1*14 and DQB1*05 because the alleles were  
present in almost all patients (39/40). 
 
Table 14 summarizes the results of correlation between HLA DR, DQ alleles and  haplotypes 
with  severity of disease in pemphigus vulgaris patients.  
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Table 14- The correlation between HLA DR and DQ alleles, haplotypes with disease 
severity 
 
Allele /haplotype 
Patients positive for the 
allele 
Patients negative for the 
allele 
P value 
No. of 
patients 
PDAI score 
(mean ± SD) 
No. of 
patients 
PDAI score 
(mean ± SD) 
 
DRB1*14 
 
39 
 
24.4 ± 23.5 
 
1 
 
3 
 
0.30 
 
DRB1*04 
 
10 
 
32.0 ± 26.8 
 
30 
 
21.2 ± 22.5 
 
0.36 
 
DQB1*05 
 
39 
 
23.8 ± 23.7  
 
1 
 
27 
 
0.70 
 
DQB1*03 
 
17 
 
33.7 ± 24.9 
 
23 
 
16.6 ± 19.8 
 
0.02 
 
DRB1*14/DQB1*05  
 
37 
 
24.5 ± 24.1 
 
3 
 
16 ± 12.12 
 
0.7 
 
DRB1*04/DQB1*03 
 
7 
 
37.8 ± 26.3 
 
33 
 
24.5 ± 23.4 
 
0.09 
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ANTIBODY  TITRES : ANTI DESMOGLEIN ANTIBODIES AND  SERUM 
IMMUNOGLOBULIN G4 
Of the 42  pemphigus vulgaris patients with active disease, immunoglobulin G4 antibody 
levels was  done in 38 patients.  
 
IgG4  levels in the pemphigus vulgaris patients ranged from 596 to 3199 mg/L with  mean 
titre of 1114.4 ± 576.01 mg/L. 
 
The serum IgG4 levels  positively correlated with the Anti-Dsg3 antibody  levels in patients 
with pemphigus vulgaris with correlation coefficient R = 0.407 and this correlation was 
significant (p = 0.01)  (Figure 9).  
Although  serum IgG4 levels showed a positive correlation  with anti-Dsg1 titres in patients 
with pemphigus vulgaris, it was not significant (p = 0.06).(Figure 10) 
 
Similarly  the correlation between PDAI score and serum IgG4 levels  showed a positive 
correlation (R= 0.19) but this was not significant (p = 0.25). (Figure 11) 
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Figure 9:  Correlation of serum IgG4 with anti-Dsg3 in 
patients with pemphigus  vulgaris  
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Figure 10: Correlation of serum IgG4 with anti-
desmoglein 1 in patients with pemphigus vulgaris 
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Correlation of   total PDAI scores with serum IgG4  in the patients with pemphigus vulgaris 
was not significant. (Figure 11) Although positive correlation was present  (R = 0.19), it was 
not significant ( p = 0.25). 
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Figure 11: Correlation of  PDAI score with serum IgG4 
in patients with pemphigus vulgaris
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In the pemphigus foliaceus   patients IgG 4 level  was  available for 17/18 patients. Serum 
IgG4 levels ranged from a minimum level of 605 mg/L to a maximum value of 7378  mg/L. 
The mean IgG4 level was 1471.14 ± 1644.32 mg/L 
 The IgG4 levels had a poor correlation with anti-Dsg1 levels in patients with pemphigus 
foliaceus. (R=0.006,  p = 0.98) (Figure 12) 
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Figure 12: Correlation between IgG4 levels and 
anti-Dsg 1 in patients with pemphigus foliaceus 
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A positive correlation between disease severity (PDAI score) and serum IgG4 antibodies was 
demonstrated in   pemphigus foliaceus patients (Figure 13). (Correlation coefficient R= 0.25, 
p = 0.03). 
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Figure 13: Correlation of  PDAI scores with serum 
IgG4 in patients with  pemphigus foliaceus   
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However there was one extreme value of  IgG4  of 7378  mg/L. On exclusion of this value 
the PDAI scores  did not correlate with the IgG4 levels in the pemphigus foliaceus patients.  
(R= - 0.16, and p = 0.54). (Figure 14) 
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Figure 14: Correlation of  PDAI scores with serum IgG4 
excluding the extreme values in pemphigus foliaceus.
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The correlation of serum IgG4 levels with disease duration in both the groups combined, 
pemphigus foliaceus and vulgaris  showed a  positive correlation but it was not of statistical 
significance (R = 0.032  and p = 0.8) Assessed individually,  the serum IgG4 levels in 
relation to disease duration also showed only  a weak positive correlation in pemphigus 
vulgaris (R is 0.032, p = 0.95). (figure 15)  
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Figure 15: Correlation between duration of disease  
and serum IgG4 in pemphigus vulgaris patients
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There was a negative correlation of disease duration with serum IgG4  seen in foliaceus 
group. (R= -0.144, p =0.58) (figure 16) 
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Figure 16: Correlation between  disease duration and   
serum IgG4 in pemphigus foliaceus patients
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On exclusion of  two extreme variables  (duration -15 years & IgG4 =7378 mg/L) , the value 
of  R was positive, R= 0.011, but this was not significant ( p = 0.93) as represented in the 
scatter plot in figure 17.  
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Figure 17: Correlation between the duration of disease and 
IgG4 in pemphigus foliaceus 
76 
 
 
 
 
 
 
 
 
  
Figure 18: Flaccid bullae and moist erosions in a 
patient with pemphigus vulgaris 
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Figure 19: Erosions on the lips in a case of pemphigus  
vulgaris 
Figure 20: Erosions on the labial mucosa in 
young female with pemphigus vulgaris 
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Figure 21: Vesicular and bullous lesions in a case of pemphigus 
vulgaris 
Figure 22: Paronychia in a case of pemphigus vulgaris 
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Figure 23: Healing erosions with marginal activity  and post-
inflammatory hyperpigmented macules in an adult with  pemphigus 
vulgaris 
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Figure 24: Eroded moist plaques in flexural region in case of 
pemphigus vegetans 
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Figure 25: Flaccid bulla and  superficial crusted erosions in a 
young adult with pemphigus foliaceus 
82 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 26: 32 year old  lady with 
erythroderma due to pemphigus foliaceus 
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Figure 27: Suprabasal bulla with acantholytic cells in blister cavity in 
pemphigus vulgaris 
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Figure 28: Subcorneal bulla with acantholytic cells in the granular 
layer in case of pemphigus foliaceus 
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Figure 29: Intercellular fish-net pattern of IgG deposits  
in DIF of perilesional skin in pemphigus 
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DISCUSSION 
 
Pemphigus is an acquired immunobullous disease involving the skin and the mucosa. The 
pathogenesis of the disease has been extensively studied. Autoimmunity is thought to play an 
important role in the pathogenesis of pemphigus. This has been supported by the 
demonstration of tissue bound and circulating autoantibodies in patients with pemphigus. 
These autoantibodies are directed against the intercellular adhesion proteins. Genetic 
predisposition also plays a significant role in the development of the disease. The role of 
genes in the predisposition to pemphigus has been repeatedly reinforced by the demonstration 
of significantly higher frequency of occurrence of   MHC class II genes in patients with 
pemphigus as compared to healthy individuals. 
 
The MHC class II genes, mainly  the HLA DRB1*04, DRB1*14, DQB1*03,  DQB1*05 
genes   have  been seen  in  patients  with   pemphigus vulgaris in  studies  from  different 
parts  of the world.  Until now there  have  been 3 studies  that have  included patients  of  
Indian origin  to assess the  HLA types in pemphigus, of which only 1 study was done in 
India. These studies have shown a higher  frequency  of  DRB1*14 genes and DQB*05. 
Studies from the Western-European population have demonstrated higher frequency of 
DRB1*04 and DQB1*03. We undertook the present study to determine the HLA DR and DQ 
types that are commonly seen in patients with pemphigus in India. 
 
Autoantibodies in pemphigus  are important in the pathogenesis of the disease. IgG 
antibodies target the intercellular adhesion proteins and  prevent their normal functioning 
thereby leading to acantholysis. IgG1 and IgG4 are the  main subclass of antibodies that are 
of  importance  in pemphigus.  It has been seen that IgG4 antibodies are the main pathogenic 
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antibodies and are present in high amounts during early  disease activity. In this study we 
attempted to  correlate the disease activity as measured by Pemphigus Disease Area Index  
with serum total IgG4 level.  
 
Seventy two patients of pemphigus were included in our study. The youngest patient in our 
study was 12 years of age. There were a total of 4 patients under the age of 20 years. Juvenile 
pemphigus is relatively rare, but pemphigus vulgaris has also been reported at  three and half 
years of age and 2 years of age, however the clinical details of the latter were not 
available.(84,85)  
  
 
Among the pemphigus vulgaris  48% had disease onset below the age of 40 years.  This 
confirms the reports of  earlier onset of pemphigus in India as compared to the European  
population where the onset of pemphigus is usually in the 5th decade.(46) The oldest patient 
had onset of disease at the age of  68 years. In Mahajan et al’s study the oldest patient 
reported was 98 years of age.(80)   In both the pemphigus vulgaris and foliaceus group of 
patients taken together the gender distribution showed an equal prevalence in females and 
males with male to female ratio 1:1. This is contrary to other Indian studies where female 
predominance ranging from 1.16 to 1.8: 1 has been reported. However when the two groups 
were analyzed separately we found   female predominance in patients in pemphigus vulgaris 
with  male : female ratio of 1:1.45.  A significant male predominance was seen in the 
foliaceus   group  with M:F ratio of  3.5:1. As the sample of pemphigus foliaceus patients was 
smaller and only patients with active disease were  recruited in the study for the purpose of  
correlating IgG4 with disease activity,  it may not reflect the true demography of   pemphigus 
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foliaceus. The comparison of demographic data between our study and other studies is 
represented in table 15. 
 
Table 15- Comparison of  demographic data between our study and other studies in 
literature. 
Parameter Present 
study 
Mahajan VK 
et al. (80) 
Kandan S et 
al(19) 
Wilson C et al(46) 
Total no. of 
patients in study  
72 54 65 50 12 
Type of study  Prospective Retrospective Prospective 
+ 
retrospective 
Retrospective Retrospective 
Year of study  2013-2014 1990-2002 2001-2008 1994 1994 
Ethnicity  Indian  North Indian South Indian North Indian European 
Age at onset  of 
disease in years 
(range) 
43.2 (12-68) N.A.(10-95)* 44.6 (14-73) 41.2 (15 -65) 52.7 (31-79) 
Male:Female 
Ratio  
 
1:1 1:1.16 1:1.82 1:1.04 1:1 
No of 
pemphigus 
vulgaris 
(percentage) 
51 (70.83%) 44 (81.48%) 49 (75.4%) 43 8 
No. of 
pemphigus 
foliaceus 
(percentage  
18 (25%) 8 (14.81%) 11 (16.92%) 4 9 
No. of 
pemphigus 
vegetans 
3 (4.16%) 1 3 (4.6%) 2 2 
Other types 
recorded 
nil 1 2 (2.1 %) 1 1 
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The disease duration on an average was 2.81 years (2.9 years in patients with pemphigus 
vulgaris and 2.4 years in  foliaceus patients). The longest duration of disease noted in our 
study was 15 years. Pemphigus is known to have a chronic course.  Activity of disease 
reduces with time and remissions may be achieved with appropriate steroid and 
immunosuppressive therapy.  Relapses usually occur within 2 years of the diagnosis.(86) 
 
There were 54 pemphigus vulgaris patients (75%) and 18 patients of the foliaceus type 
(25%). This is similar to other studies reported from India where pemphigus vulgaris  has 
been reported to constitute 72 to 95% of all cases of pemphigus.(87) Wilson et al in their 
study found that there were equal number of pemphigus foliaceus and vulgaris cases in the 
population from UK, while the population from New Delhi had 43 vulgaris cases out of the 
50 pemphigus patients.(46) 
 
The onset of disease in patients with pemphigus vulgaris was the  oral mucosa in majority 
(81.48%)  of the patients.  This percentage is higher than Gupta et al’s study where in 65% of 
cases mucosal lesions preceded the development of cutaneous lesions. In 2 other studies from 
India 50% cases had oral involvement as the primary manifestation. The duration between 
mucosal involvement to the development of cutaneous lesions can vary between 6-9 
months.(80,88) Wilson et al reported that all patients of pemphigus vulgaris had eventually 
developed oral lesions.(46) 
 
Of 42 patients with active disease, oral mucosal involvement was seen in 83.3% of patients 
and skin was involved  in 61.1% of patients at the time of recruitment in the study. Patients 
with oral erosions more often present with pain and those with skin lesions often present with 
pruritus. Pruritus  was reported in 18% of  pemphigus vulgaris  cases in a study  of   75 cases 
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of pemphigus done  by Vora et al.  Pruritus was present in 100% of the pemphigus foliaceus 
patients in their study.(74) 
 
The history of photosensitivity   was present in 11.1% of patients of pemphigus vulgaris and 
16.6% of pemphigus foliaceus. Photosensitivity is more often reported with pemphigus 
foliaceus and  exacerbation of the disease with UV exposure was reported in a case-
series.(89) In most studies on pemphigus the diagnosis of pemphigus erythematosus has been 
a clinical one without the DIF features to support it. The direct immunofluorescence features 
in 7 out of these 9 patients was not suggestive of pemphigus erythematosus. ANA was done 
in 5 of the 9 patients and was negative in all the 5.  ANA  in pemphigus vulgaris patients has 
been reported positive in 26.7% of cases.(90) 
 
The  history of a possible drug trigger was present in a single patient of pemphigus vulgaris.   
The suspected drug was enalapril. The thiol group of drugs are known to trigger 
pemphigus.(67) Drug induced pemphigus has not been commonly reported  in Indian studies,  
probably due to the low index of suspicion. Also drug induced pemphigus is difficult to 
diagnose in the absence of   specific diagnostic test.  
 
The well known associations of pemphigus include myasthenia gravis, thymoma, lupus 
erythematosus and  neoplasia in case of paraneoplastic pemphigus.(3) In our study, 72.2% of 
had associated comorbidities.  Hypovitaminosis D was the commonest associated comorbid 
condition, which was present in 27 patients (35.5%). This association is probably fortuitous 
and may be attributed to the generally high prevalence of vitamin D deficiency in India.(91) 
Diabetes mellitus type -2 was seen in 33.3% patients and hypertension in 18 patients (25%), 
while osteopenia and osteoporosis was present in 9.7% cases. Hypothyroidism was present in 
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3 patients. Other conditions that  were a chance occurrence, seen in one patient each were 
hepatitis C,  HIV,   bronchial asthma, atopy and adjustment disorder. Single patient  at the 
time of  inclusion  had retroperitoneal fibrosis, and six months later was found to have non-
Hodgkin’s lymphoma, however the clinical features, histopathology and direct 
immunofluorescence findings were consistent with pemphigus vulgaris type, thus 
paraneoplastic pemphigus was ruled out. Gupta et al reported  autoimmune  conditions in 
association with pemphigus vulgaris in 20.5% of cases. Thyroid dysfunction was reported in 
45% of their study population, the other autoimmune associations being rheumatoid arthritis,  
alopecia areata,  type 1 diabetes mellitus, and  one patient each with  lupus erythematosus, 
myasthenia gravis and  vitiligo.(14) 
 
Ninety-three percent of  patients in our study were  on treatment with steroids prior to 
inclusion in the study.  Steroid therapy was most often instituted orally. Twelve patients had 
received  dexamethasone- cyclophosphamide pulse therapy with  inter-pulse oral steroids.    
 
We found the most common  steroid sparing adjuvant used was azathioprine (50.7%). It is a 
well established adjuvant with equal efficacy to mycophenolate mofetil (MMF), but provides 
relatively faster disease control.(92) Only 2 patients  had received  MMF. Mycophenolate 
mofetil,  is considered to have a better side effect profile, and has been considered the first 
choice for adjuvant in pemphigus in  patients with mild to moderate disease severity.(93) 
Cyclophosphamide was used in 17.8% of patients. Daily  administration of 
cyclophosphamide is said to have the best disease control but is also associated with higher 
cumulative toxicity.(94) Methotrexate is infrequently  used in treatment of  pemphigus, but 
has proven efficacious in improving disease in over 90% patients.(95)  In our study 5 patients  
had received  methotrexate in the past. One of these 5, a  patient of pemphigus vulgaris,  had 
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been on methotrexate for 2 years and had good control of the disease with anti-desmoglein 
antibody levels  of <2u/mL. 
 
Oral mucosal involvement was seen in 83.3%  cases. This is in concordance with other 
studies where the involvement of mucosa  has been reported in 75% , 78.3% to 
97%.(14,19,80)   Three cases were  mucosal predominant pemphigus (5.5%), and there was 
one patient with cutaneous pemphigus vulgaris, 92.6% were mucocutaneous type of 
pemphigus vulgaris. Mucocutaneous pemphigus is the most common clinical type of 
pemphigus vulgaris. It was seen in 63.63% in Mahajan et al’s study, 65.85% in Gupta et al 
study.(14,80)   Wilson et al reported that mucosal lesions developed in all cases of pemphigus 
vulgaris from India as compared to 8 of 10 cases from UK.(46) Gupta et al reported that scalp  
was the most common site of involvement followed in frequency  by lesions on the trunk.(14) 
In our study, trunk was the most common site of involvement 73.8%,  scalp involvement was 
seen in 47.6%.  Nail involvement in pemphigus is less common, but its presence is  
associated with severe disease.(96,97) It  was seen in  16.6% cases in our study. 
 
Of the pemphigus foliaceus group, one patient had erythroderma. Mahajan et al reported one 
case of erythrodermic pemphigus foliaceus in his study of 54 cases.  Erythroderma in 
pemphigus is more often associated with  endemic forms of  pemphigus foliaceus and less 
frequently with  non- endemic pemphigus foliaceus.(3) Although pemphigus foliaceus has a 
benign course as compared to vulgaris, when in erythroderma it can prove to be fatal.(98) 
 
Nikolsky sign was positive in 18% of pemphigus vulgaris patients and 50% of foliaceus 
patients. Nikolsky sign is not very sensitive but is a relatively specific sign for pemphigus. 
Arya et al in their study on 70 pemphigus cases, reported Nikolksy sign posit ive in 97.2% of 
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vulgaris  patients and 94.7% in foliaceus  patients.(99) The lower rate of  positive Nikolksy 
sign in our study is probably because patients were already on treatment prior to inclusion in 
the study. 
 
The   PDAI score in  patients with pemphigus  vulgaris  ranged from 1 to75  with a mean 
score of  24.1. Among the pemphigus foliaceus   patients the PDAI scores ranged from 3 to 
88 in most patients, and maximum score of 105 in the erythrodermic patient. The  mean score 
in foliaceus patients was 33.8. Overall the mean PDAI scores was not very high since most 
patients were on treatment. Mean PDAI scores in our patients was higher than that seen in 
Rosenbach et al’s study of 15 patients of pemphigus vulgaris (24.1 versus 10.2).(82) Their 
study included pemphigus vulgaris  patients with  mild to moderate disease.  Mean PDAI 
scores in our pemphigus vulgaris patients was  lower than that  seen in Chams –Davatchi et 
al’s study on 56 pemphigus. The mean PDAI of pemphigus vulgaris patients was 53.2 in their 
study. This was  probably because  treatment naïve patients were included in their trial.(100) 
 
Tzanck smear is an easy and rapid diagnostic test available for pemphigus. Tzanck smear was 
positive for acantholytic cells in 70.7 % cases in our study.  Our result was comparable to   
Patel et al’s results of 75% positivity of Tzanck smear.(101) Leena et al reported 100% 
positivity of  Tzanck smear   in their clinicopathological case series.(102) Biopsy was 
confirmatory of pemphigus vulgaris in 88.4%  cases, while in the remaining cases the typical 
features of pemphigus vulgaris was not seen. This was probably because  biopsy was not 
from an early vesicular lesion. Leena et al reported typical suprabasal bulla with acantholytic 
cells in 94.4% cases. In a study done by Arundhati et al on clinical histopathological and 
immunofluorescence features in immunobullous diseases they reported typical 
histopathological features in 26 of the 36 cases in pemphigus vulgaris and 4 of the 10 cases in 
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pemphigus foliaceus.(84) In our study histopathology was contributory  of pemphigus 
foliaceus in 100% cases in whom it was done.  
 
Direct immunofluorescence was positive for IgG  in 100% cases of pemphigus foliaceus, 
however C3 was present only in 44% of the cases.  Whereas in the vulgaris group IgG was 
detected  in 40 cases (85%)  and complements in 33 cases 70%. Arundhati et al found DIF to 
be positive in 92% of the vulgaris patients and 75% of foliaceus patients. Overall direct 
immunofluorescence was negative in 34% of  their cases. They emphasized the fact that none 
of these investigations done alone is diagnostic  in each and every disease, therefore the 
diagnosis of immunobullous disease is made by combination of clinical features, Tzanck 
smear, histopathology and immunofluorescence.(84) The reason for negativity of DIF may  
be a delay in tissue processing after sampling if it is not preserved in appropriate media. The 
other reason may be effect of  initiation of immunosuppressant.  
 
ELISA anti-desmoglein antibodies are specific for the disease, and are also found to correlate 
with the disease phenotype. In our study the Anti-Dsg 3 antibody  titres correlated positively 
with the PDAI scores in patients with pemphigus vulgaris. Similarly the anti-Dsg1 antibody 
titres showed a positive correlation with PDAI scores of pemphigus foliaceus patients. This is 
similar to study done by Kumar et al, where desmoglein ELISA titres was correlated with 
severity of skin disease in 38 vulgaris and 6 foliaceus patients.  They found that high anti-
Dsg3 titres correlated with severe  mucosal involvement in pemphigus vulgaris and anti-Dsg1 
titres correlated well the severe skin involvement. The   antibody titres,   however,   remained  
high even 6 months after resolution of skin lesions.(60) The correlation between desmoglein 
antibodies and severity was also attempted by  Harman et al’s study on 88 pemphigus 
vulgaris and 24 foliaceus cases. Harman et al demonstrated 34% chance of having higher skin 
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severity score and 25% chance of higher mucosal severity score with 10 unit rise in anti-Dsg3 
and anti-Dsg1 antibodies respectively.(81) 
 
In our study, the serum total immunoglobulin G4 antibody  titres  in the  38 pemphigus 
vulgaris patients  did not correlate with  the disease severity scores.  On the other hand in the 
pemphigus foliaceus  patients the serum IgG 4 titres had a positive correlation with PDAI 
scores. This result however was affected by an extreme value of IgG4 (7378mg/L) which was 
associated with the erythrodermic patient. On excluding this value there was no correlation 
between disease severity and the antibody titres.  The correlation of disease  severity scores 
with total IgG4  has not been studied before.  In view of the positive correlation of anti-
desmoglein antibodies with PDAI in this study   we can infer that desmoglein specific IgG4 
may show a good correlation with disease activity.  Since the desmoglein specific IgG4 was 
not available at our Institute we   tested for total IgG4 levels. The other possible reason  for 
this may be that  most of the patients had already been initiated on immunosuppresant. As 
Dhandha et al has demonstrated the IgG4 antibodies fall more rapidly when IgG1 antibodies 
when the disease remits.(63) 
 
We did not find a positive correlation between disease duration and serum total IgG4 levels 
in our patients. Although a positive correlation was noted in pemphigus foliaceus patients on 
exclusion of extreme value of serum IgG4 titre, the correlation was not significant to draw 
any conclusions. This result was contrary to Dhandha et al’s finding of higher IgG4 levels in 
patients with longer disease duration. Dhandha et al proposed that serum anti-desmoglein  
IgG4 levels  rise  with longer duration of disease.(63) 
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Table 16-Baseline characteristics of studies on HLA types in Pemphigus 
 
NA = data not available from study,  R= related, UR=unrelated controls,  PCR SSOP-
Polymerase chain reaction, sequence specific oligonucleotide probe, SSP-sequence specific 
primers, RFLP-restriction fragment length polymorphism, IIF-indirect immunofluorescence, 
HPE-histopathological examination, DIF- direct immunofluorescence. 
Study Ethnicity 
Diagnostic 
criteria 
No. of 
cases 
No. of 
controls 
Genotyping 
method 
Present 
study  
Indian  Clinical + 
HPE/ DIF/ Dsg 
ELISA 
50 50 (UR) PCR SSOP 
Delgado et 
al(34) 
Indian Clinical + IIF 39 89 (R ) PCR SSOP 
Delgado et 
al(39) 
Pakistani Clinical +IIF 19 13(UR) PCR SSOP 
European Clinical +IIF 38 496(UR) PCR SSOP 
Miyagawa 
et al (38) 
Japanese Clinical +HPE/ 
DIF /IIF 
16 525(UR) PCR RFLP 
Saha et al(6) Caucasian 
European 
NA 96 100(UR) PCR SSP 
Indo-Asian NA 57 59(UR) PCR SSP 
Shams et 
al(31) 
Iranian Clinical + 
HPE/ DIF 
52 180(UR) PCR SSP 
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Table 17- Comparison of the predominant HLA DRB allleles  (allele frequency in % )  
between our study and other studies on pemphigus 
 
NA = data not available  NS=not significant, but p value not mentioned in study 
Con=controls    asignificantly high in controls. 
 
Study 
title 
DRB1*14 DRB1*04 DRB1*15 DRB1*11 
case con p case con p case con p case con p 
Present 
study 
94 36 <0.00
1 
26 16 0.2 14 32 0.01a 4 18 0.02a 
Delgado 
et al(34) 
45.9 13.5 <0.00
1 
NA NA NA NA NA NA NA NA NA 
Delgado 
et al(39) 
55.3 23.1 0.01 10.5 34.6 NS NA NA NA 0 7.7 NS 
36.8 4.2 <10-6 23.7 15.3 NS NA NA NA 5.3 11.1 NS 
Miyagaw
a et al(38) 
27.6 6.8 <0.05 43.8 6.7 <0.05 NA NA NA NA NA NA 
Saha et al 
(6) 
46.5 11.9 <0.00
1 
14 0.8 <0.00
1 
4.4 21.2 <0.001
a 
NA NA NA 
22.9 4.0 <0.01 37 14 <0.01 4.2 12.5 <0.01a NA NA NA 
Shams et 
al(31) 
25 5 <0.01 36.5 9.2 <0.01 NA NA NA 13.5 24.7 0.01a 
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As presented in the table 17 the HLA DRB1*14 is significantly higher in  pemphigus patients 
as compared to controls in  most  ethnic groups. In our study HLA DRB1*14  allele 
frequency was significantly higher in pemphigus patients (47 of 50cases)  as compared to that 
in controls (17 out of 50) (p value <0.001). Nine  patients of the 47  were homozygous for 
this allele.  
 
Our  results were   consistent with  Delgado et al’s study on Indian patients of pemphigus 
vulgaris where HLA DRB1*14 was the most frequently seen  DRB allele.(34) The 
association of HLA DRB1*14 with  pemphigus was also supported by Yan et al’s meta-
analysis that included  18 studies from different parts of the world.(30) Saha et al’s study 
population was divided into White Europeans (Caucasians) and Indo-Asians.(6)  Their study 
also confirmed that  DRB1*14 is more often associated with  pemphigus patients of Indo-
Asian origin as compared to their Caucasian  population.  However the percentage of patients 
that were of  Indian origin was not mentioned. 
 
The  DRB1*04 allele was  found to be slightly increased in  our patients (26%)  as compared 
to in  normal individuals (16%), however this  difference was not statistically significant. 
This allele   is seen   more often in the  Ashkenazi Jewish and in most Non-Jewish  Caucasian 
population.(73)  Specifically,  DRB1*0402  is  the allele that is identified with susceptibility 
to  pemphigus in Ashkenazi Jews.(33) DRB1*04  was  not  reported in Delgado et al in his 
study on  Indian pemphigus patients.(34)  In Saha et al’s study DRB1*04 was found to  be 
significantly increased in the Indo-Asian population. This may have been due to the  varied 
ethnicity and  this study  cannot be taken to truly reflect the genotype of pemphigus patients 
of Indian race.(6) The meta-analysis by Yan et al also reported significant association of 
DRB1*04 with pemphigus patients from different ethnic populations. DRB1*0402, apart 
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from the Jewish population was seen to be associated with pemphigus patients of European 
and Iranian origin, whereas DRB1*0403 and DRB1*0404 were associated with the Japanese 
population.(30) 
 
 The  increased frequency  of HLA DRB1*15  in controls (32%) versus  pemphigus patients 
(14%)   that was seen in our study is also  noted in  Saha et al’ s study, as seen in both their 
study groups.  The negative association of the allele DRB1*15 is confirmed by the meta-
analysis by Yan et al.(30)  The  other allele that was  increased in controls as compared to 
patients  in our study population was DRB1*11   (p = 0.02). This is a relatively rare negative 
association, but has also  been noticed in study by Shams et al on patients of Iranian 
origin.(31)  Yan et al’s meta-analysis found sufficient evidence for  other alleles that have 
been  negatively associated with pemphigus and therefore thought to have a protective role in 
pemphigus. These include  DRB1*07 and DRB1*03.(30)  Of these  DRB1*07 was found to 
be slightly  increased in controls (14/50) as compared to patients (8/50)  in our study but not 
in percentages that would reach  significance level.  DRB1*03 was noted in only in 3 controls 
and 1  pemphigus patient in our study. The frequency of  DRB1*15 and DRB1*11 which 
were increased in our control population was  not found in Delgado et al’s study.(34) 
 
In a different  study by Delgado et al HLA types in  pemphigus patients from Pakistan and a 
set of Non –Jewish Caucasian population was studied.(39) This study also reported DRB1*14  
to be significantly higher in pemphigus patients from both  ethnicities. Interestingly their 
study, similar to our study, did not show a significant increase in  DRB1*04  in the Pakistani 
or the Caucasian population.  
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As expected  from other Asian countries, the study on Japanese population has also shown 
results similar to our study with respect to  DRB1*14. In addition to  DRB1*14, DRB1*04 
was also significantly high in the Japanese pemphigus patients.(38) 
Table 18- Comparison of HLA DQB1  alleles (allele frequencies in %) between present 
study and other studies on pemphigus  
Study title 
DQB1*05 DQB1*03 DQB1*06 
case con p case con p case con p 
Present study 94 48 <0.001 48 50 0.86 16 38 0.02a 
Delgado et 
al(34) 
48.6 17.9 <0.001 16.2 7.9 NS NA NA NA 
Delgado et 
al(39) 
57.9 26.9 0.02 7.9 15.4 NS 5.2 7.6 NS 
36.8 4.3 <10-6 23.7 9.2 NS 5.3 4.8 NS 
Saha et al (6) 32.8 9 <0.001 22.4  4.0 <0.001 3.1  11.5 0.002a 
47.4  12.7 <0.001 15.8  6.8 0.049 4.4   15.3 0.011a 
Miyagawa et 
al(38) 
31.2 4.8 <0.05 50 17.1 <0.05 NA NA NA 
Shams et 
al(31) 
18.25 2.5 <0.001 32.7 5 <0.001 0.95 10.3 0.004 
 
Con – controls,  NA=data not available from study, NS =not significant, p value not 
mentioned in study,  asignificantly high  in controls. 
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Among the different DQB alleles we found significant increase in DQB1*05 in our 
pemphigus patients (94% cases and 48% controls) (p value <0.001).(Table 18) Ten patients 
showed homozygosity for the presence of  DQB1*05. Our  result is consistent with  other 
studies that have looked at DQB alleles in pemphigus. (5,31,34,38,39) Delgado et al’s study  
on Indian patients found significant association  of DQB1*05 in pemphigus patients.(34) In 
the study on Pakistani and Caucasian patients by the same author,  DQB1*05 was  reported 
highly significant in the Caucasian population  and  in lower levels of significance (p value 
=0.02) in the Pakistani population.(39)   HLA DQB1*03    is the other allele that  is reported 
to have a strong association with pemphigus patients. In our study  DQB1*03 was  found in  
nearly equal  frequency in patients (24/50)  and controls ( 25/50).   Our results with respect to 
this HLA type was similar to the result of  Indo-Asian population in Saha et al’s study. They 
reported the allele in higher frequency  in the Caucasian population, but not in Indo-
Asians.(6) The study on Iranian as well Japanese population  has also provided  evidence for 
the association of DQB1*03 with pemphigus.(31,36) 
 
We also noted higher frequency of  DQB1*06 in  controls (38%) versus patients (16%), 
although the strength of the difference was relatively marginal (p value = 0.02) This result 
was in  keeping with  the results of the other studies.(Table 18) Saha et al found  similar  
negative association of DQB1*06 in both the Indo-Asian as well as the Caucasian 
population.(6) The same was also noted in the Iranian population.(31) However DQB1*06 
was  not reported from the study on  Japanese  patients.(38) In Delgado et al’s study  the 
representation of this  allele did have significant  difference between patients and controls of  
both the Pakistani and the Caucasian series.(39) 
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Table 19- Comparison of  haplotype frequency (in %) between our study and other 
studies on pemphigus  
 
Study title 
DRB1*14, DQB1*05 DRB1*04, DQB1*03 DRB1*15,DQB1*06 
Cases Controls P Cases Controls P cases controls P 
Present 
study 
88 28 <0.001 24 12 0.13 10 30 0.018a 
Miyagawa 
et al (38) 
31.2 4.7 <0.01 43.8 6.7 <0.001 NA NA NA 
Shams et 
al (31) 
25 4.4 <10-3 36.5 5.8 <10-3 0.95 6.4 0.02a 
astronger significance in controls.  
 
 
 
 
 
 
 
 
103 
 
Haplotype analysis in our study revealed a statistically strong association for the haplotype 
DRB1*14 DQB1*05  with pemphigus (88% patients and 28% controls).  Our result is 
consistent with that of  other studies that  have analyzed   haplotypes in pemphigus patients. 
(5,31,38).(Table 19) Delgado et al have also mentioned  the occurrence of  DRB1*14 and  
DQB1*05 together  to have strong association with pemphigus patients in both of their study 
groups,  Pakistani  (p  <10 -6) and Caucasians  (p = 0.01), however the exact percentages was 
not mentioned for this data.(39) This study  provided evidence for the presence of 
autoantibodies in subjects who carried this haplotype, emphasizing its pathogenic role.  They 
also noted the haplotype DRB1*04, DQB1*03 in 9 of the non- Jewish Europeans, although of 
no statistical significance.    
The haplotype DRB1*04/DQB1*03   was increased in number in  patients (24%) as 
compared to the controls (12%) in our study,   but this difference failed to achieve 
significance levels at p <0.05. This was unlike the results  on Japanese and Iranian patients.  
It is identified  as the characteristic haplotype of Ashkenazi Jews  that predisposes them to 
higher incidence of pemphigus. The haplotypes that are probably relevant  in  disease 
causation  include DQA1*0505 that occurs in association with DRB1*04 and DQB1*03. 
Another of the DQA allele is the DQA1*0101 which  appears frequently with DRB1*14 and 
DQB1*05. However in our study we did not test for DQA1 alleles.  
 
The allele DQB1*03 was associated with more severe disease as seen by higher PDAI scores 
in patients carrying this allele (p = 0.02), despite  the  fact  that the allele frequency did not 
reach significance levels when compared  to  control population. This finding was similar to 
the  results of Svecova et al’s recent study.(104) The  severity of disease was measured by  
ABSIS score in this study. They demonstrated a strong association between severe   disease 
and presence of DQB1*03 allele. They also found similar association for DRB1*04. Our 
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study was dissimilar in that respect, patients with  DRB1*04 did not have   high  scores of  
PDAI. Svecova et al’s study also demonstrated an  association between the DRB1*1454 with 
male gender, which  has not be reported before.  Such a difference in DR or DQ allele  with 
respect to gender  was not seen in our  study.  
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CONCLUSIONS 
 
1. Pemphigus vulgaris was the most common type of pemphigus  seen in  our study (75%), 
in keeping with  other studies from India. Pemphigus foliaceus was the second most 
frequent type of pemphigus seen in our study.  Less common variants, like pemphigus 
vegetans was seen in 4.1%. 
 
2. Majority (48%) of the pemphigus vulgaris patients had the disease onset at less than 40 
years of age, while the average age at onset was higher in the foliaceus patients (45years). 
 
3. Slight female predominance is seen in pemphigus vulgaris M:F ratio of 1:1.54. 
 
4. Oral mucosa was the most common site of onset of disease in pemphigus vulgaris as 
reported by 81.6% patients. Pain was the most common symptom associated with it. 
Pruritus was the most common symptom in pemphigus foliaceus patients. 
 
5. Vitamin D deficiency, diabetes mellitus type 2 and hypertension were the three most 
common associated comorbid conditions.  
 
6. The histopathological features were typical of pemphigus vulgaris in 88.4% of pemphigus 
vulgaris patients and in 100% pemphigus foliaceus patients. DIF was positive in 91.5% 
cases of  pemphigus vulgaris and in 100% of pemphigus foliaceus.   
 
7. Ninety four percent of pemphigus patients were carriers for  HLA DRB1*14 on at atleast 
one allele, and 18% were homozygous for it. Ninety four percent of cases had at least one 
DQB1*05 allele and 20% were homozygous for it. Strong statistical association was 
present for DRB1*14 and  DQB1*05 in pemphigus patients as compared to controls (p 
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<0.001). It was also reflected in haplotype frequency. This was in keeping with data from 
other genotype studies on pemphigus patients. 
 
8. The DQB1*03 showed significant association with severity of disease (p = 0.02), but the 
allele was seen only in 48% patients.  
 
9. Anti-desmoglein 3 antibodies showed a positive correlation with PDAI scores in 
pemphigus vulgaris patients and anti-desmoglein 1 antibodies showed a positive 
correlation with PDAI scores in pemphigus foliaceus patients. 
 
10.  The serum total IgG4 titres  did not significantly correlate with disease duration or  PDAI 
scores in both pemphigus vulgaris and foliaceus patients in our study. One probable 
reason for this discrepancy is that we tested for serum total IgG4, not specific to 
desmogleins. The other reason maybe the effect of prior treatment with 
immunosuppressants that had reduced the antibody  response. 
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LIMITATIONS 
 
Desmoglein specific IgG4 levels was not available which may have affected our results.  
There were very few treatment naïve patients, therefore the antibody response and its 
correlation with disease severity may not reflect the true nature of disease.  
We did not have HLA typing of high resolution, therefore the subtypes of DRB1, and DQB1 
could not be studied. 
The HLA DQA types were not studied.  
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RECOMMENDATIONS 
 
Desmoglien specific IgG4 would probably  better  reflect the  disease severity and serial 
estimation  of the antibody levels could be used  to guide treatment in patients with 
pemphigus. 
HLA DRB1*14 and DQB1*05 alleles are strongly associated with pemphigus and  can be 
done in relatives of patients with pemphigus to look for susceptibility to pemphigus.  
Subtype of HLA DR and DQ and other genes such as the DQA and non –HLA genes should 
be further studied in the Indian population for better insight to cause of disease. 
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SUMMARY 
 
Introduction: Pemphigus is a chronic autoimmune blistering disease that affects the skin and 
the mucosa. The disease is characterized by loss of adhesion between keratinocytes of the 
epidermis. Genetic predisposition and autoimmunity play an important role in the 
pathogenesis of the disease.  HLA DRB1*04, DRB1*14 and DQB1*03 and DQB1*05 are 
reported to have a significant association with pemphigus vulgaris. The genetic predisposition 
varies with ethnicity. We undertook the present study to find out the HLA DR and DQ types  
that are seen in association with pemphigus vulgaris in India. 
 
Antibodies against desmoglein in pemphigus are of the IgG class. Of the different subtypes, 
IgG4 is found to be raised in active phase of the disease whereas IgG1 remains elevated even 
during remission of disease. In the present study  the correlation between  severity of disease 
as assessed by PDAI in patients with pemphigus vulgaris and pemphigus foliaceus  and 
serum IgG4 levels was also evaluated.  
 
Objective : The primary objective was to compare the HLA DR and DQ types of pemphigus 
vulgaris patients with that of normal healthy subjects. 
The secondary objective was to look at the correlation between disease severity in pemphigus 
vulgaris and foliaceus,  measured by PDAI with serum total IgG4 levels.  
 
Method : This study was a prospective case-control study done in a tertiary level hospital in 
India. The study period was 10 months (November 2013 to August 2014). All patients 
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diagnosed to have pemphigus vulgaris based on clinical, histopathological, direct 
immunofluorescence or serological evidence were included in the study. HLA DR and DQ 
typing was done by PCR-SSOP method. HLA types for controls was chosen from healthy 
renal transplant donors. Pemphigus foliaceus patients with active disease were included to 
study the secondary objective.  Serum IgG4 was done in all patients with active disease. Chi-
square test was used to analyze the frequencies of various HLA DR and DQ types between 
cases and controls. Spearman Rho was used to correlate the serum IgG4 levels and PDAI 
scores. Mann-Whitney U test was used to look for the association between HLA types and 
disease severity.  
 
Results :  The study included 72 patients, 54 (75%) had pemphigus vulgaris and 18 (25%) 
had pemphigus foliaceus.  The mean age at disease onset for pemphigus vulgaris patients was 
39.2 ±13.3 years with male to female ratio of 1:1.45. In the pemphigus foliaceus group the 
mean age at disease onset was 44.3 ±  12.9 years, male to female ratio of 3.5:1.  In 82%  
pemphigus vulgaris patients the site of onset was oral mucosa. Mucocutaneous pemphigus 
was present in 92.5%, mucosal predominant in 5.5% and cutaneous predominant pemphigus 
in 1%.  The mean  PDAI score was 23.5  (range,1 to 75)  in pemphigus vulgaris  patients and 
33.8 (range, 3 to 105)  in pemphigus foliaceus patients. 
 
Typical features of on histopathology was seen in 88.4%  pemphigus vulgaris cases and 
100% foliaceus cases. DIF was positive in 91.4% vulgaris patients and 100% foliaceus 
patients. The mean anti-Dsg1 and anti-Dsg 3 levels in patients with pemphigus vulgaris was 
147.01 u/mL and 60.8 u/mL respectively.  The anti-Dsg3 levels showed a positive correlation 
with the PDAI scores in pemphigus vulgaris patients (p <0.001).  The mean anti-Dsg1 in 
pemphigus foliaceus was 177.14 and it correlated positively with PDAI scores (p  <0.01).  
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HLA typing was done in 50 patients and compared to 50 controls. Significant association was 
seen with DRB1*14 and DQB1*05 with pemphigus vulgaris patients.   HLA DRB1*14  was 
present in 94%  cases and 36% controls (p  <0.001).  HLA DQB1*05 was present in 94% 
cases and 48% controls (p <0.001). The haplotype DRB1*14, DQB1*05 was present in 88% 
cases versus 28% controls (p <0.001).  Negative association was found with DRB1*15 (14% 
cases versus 32% controls, p <0.05) and DQB1*06 (16% cases versus 38% controls, p<0.05).  
 
HLA DQB1*03 was associated with more severe disease. 
Mean serum total IgG4 in pemphigus vulgaris patients was 1114.4 ±576 mg/L. Serum IgG4 
levels had a positive correlation with anti-Dsg3 antibody levels (p <0.01). There was a 
positive correlation between PDAI and IgG4 levels but did not reach significance levels. 
 
Mean serum total IgG4 in pemphigus foliaceus patients was 1471.14 ± 1644.3 mg/L.  It did 
not have a significant correlation with PDAI scores.  
 
Conclusion: Pemphigus vulgaris is the most common type of pemphigus seen in India. The 
average age at onset of disease is similar to that reported from other Indian studies, and is 
lower  than that reported from other parts of the world.  Slight female predominance is seen 
in pemphigus vulgaris. HLA DRB1*14 and DQB1*05 alleles and the haplotype DRB1*14, 
DQB1*05 are strongly associated with pemphigus vulgaris. DQB1*03 is associated with 
more severe disease. Serum Dsg-3 levels correlated positively with PDAI scores in 
pemphigus vulgaris while anti-Dsg1 levels correlated with PDAI scores of pemphigus 
foliaceus patients. There was a weak association between serum total IgG4 levels and disease 
severity scores in pemphigus vulgaris but the same was not demonstrated in pemphigus 
foliaceus. 
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ANNEXURE 1 
DATA  ENTRY  PROFORMA  
 
STUDY  OF   HLA TYPES  AND SERUM  IMMUNOGLOBULIN G4  IN PEMPHIGUS    
DATE :                                               STUDY NO:         HOSPITAL NO: 
NAME :     AGE :   SEX:               M=1, F=2 
ADDRESS :      
FIRST VISIT/   REVIEW 
Active disease / remission 
DURATION OF  ILLNESS: ____________________________ 
SITE OF ONSET OF LESIONS :  1= MUCOSA / 2= SKIN/ 3=  SCALP/ 4=NAILS 
SYMPTOMS : 1= PAIN / 2=  PRURITUS/ 3= BURNING  
PHOTOSENSITVITY :  1=PRESENT / 2=ABSENT 
DRUGS INDUCING / AGGRAVATING   PEMPHIGUS :  PRESENT / ABSENT 
 DETAILS …………………………… 
TREATMENT  RECEIVED :   
 1= STEROIDS :  ORAL /  INJECTABLE    
MAXIMUM  DOSE OF STEROIDS  (…..mg/kg) : 
                             DURATION ………… 
2 = STEROID SPARING DRUGS ( WITH DOSE AND DURATION) 
 
 
DRUG DOSE DURATION RESPONSE/ COMMENT 
AZATHIOPRINE   
 
   
CYCLOPHOSPHAMIDE 
 
   
METHOTREXATE 
 
   
MYCOPHENOLATE    
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MOFETIL 
 
  IVIG 
 
   
RITUXIMAB  
 
 
   
Currently on… 
Stopped drugs when / how long back 
ASSOCIATED COMORBIDITIES :  present / absent 
If Present-  
THYMOMA/   MYASTHENIA GRAVIS/   
 DIABETES MELLITUS/   HYPERTENSION  /   CORONARY ARTERY DISEASE  / 
METABOLIC SYNDROME  /THYROID DYSFUNCTION                                                                             
OTHERS-SPECIFY- 
FAMILY HISTORY  OF PEMPHIGUS :  1= PRESENT/ 2=ABSENT 
    (SIBLING/PARENT/CHILDREN) 
 
EXAMINATION 
 
SKIN ::  
SITES  INVOLVED -   FACE/   TRUNK/ LIMBS/ FLEXURES/ GENITALS 
   LESIONS – BULLAE /  EROSIONS/  HYPERPIGMENTED MACULES/ 
   ACANTHOMA/  VEGETATING LESIONS 
SECONDARY INFECTION : 1= PRESENT/ 2= ABSENT 
MUCOUS MEMBRANES INVOLVED -- 
ORAL :  LABIAL/ BUCCAL/ GINGIVAL/ TONGUE/ FLOOR OF MOUTH   /                                              
PHARYNX 
NASAL ; INVOLED / NOT INVOLVED 
CONJUNCTIVA: 1=INVOLVED,  1.A=UNILATERAL, 1.B =BILATERAL  
                              2=NOT INVOLED 
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GENITAL MUCOSA: 1=INVOLVED /  2=NON INVOLVED 
SCALP ; 1= INVOLVED /  2=NOT INVOLVED 
NAILS : PERIONYCHAL LESIONS  1=PRESENT/2= ABSENT 
 NIKOLSKY’S SIGN :   DIRECT::  1=POSITIVE /   2=NEGATIVE 
   PERILESIONAL:: 1=POSITIVE/ 2=NEGATIVE 
BULLA SPREAD SIGN : 1=POSITIVE /   2=NEGATIVE 
 
INVESTIGATIONS  
VITAMIN D LEVELS: 
DESMOGLEIN 1 : 
DESMOGLEIN 3 : 
SERUM  IgG4 : 
TZANCK : 
BIOPSY : 
 
DIF : 
 
HLA TYPE :   DR…. DQ….. 
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ANNEXURE 2 
PEMPHIGUS   DISEASE  ACTIVITY INDEX 
PDAI –SKIN  : 
ACTIVITY SCORE      0= absent,  
                                       1=1-3 lesions,  upto 1>cm    none>6cm 
                                       2=2-3 lesons,  at least 2>2cm,  none >6cm 
                                       3= >3 lesions, none >6cm 
                                       5 = >3lesions,  and/or at least one >6cm 
                                      10 = >3lesions,  and/or at least one >16cm/ entire area.  
 
Anatomical location                         Activity score 
Ears  
Nose  
Rest of face  
Neck  
Chest   
Abdomen  
Back/buttocks  
Arms  
Hands  
Legs  
Feet   
Genitals   
Total skin (   /120)  
 
 
PDAI- SCALP  EROSION/ BLISTER OR NEW ERYTHEMA 
  0= absent           
  1=  one quadrant 
  2= two  quadrants 
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  3= three quadrants 
  4=whole scalp 
  10= at least one lesion >6cm 
DAMAGE SCORE – PIH, ERYTHEMA FROM RESOLVING LESION 
                                     0=Absent 
                                     1= Present. 
Anatomical location Damage score 
Ears  
Nose  
Rest of face  
Neck  
Chest   
Abdomen  
Back/buttocks  
Arms  
Hands  
Legs  
Feet   
Genitals   
Scalp  
Total skin (   /120)  
 
 
 
 
 
 
 
 
129 
 
PDAI- MUCOUS MEMBRANES  - erosions/ blisters. 
                                              0=absent                1= 1 lesion           2= 2-3 lesions 
                                               5= >3 lesions or 2 lesions >2cm         10= Entire area    
Anatomical location Activity score 
Eyes   
Nose   
Buccal mucosa   
Hard palate   
Soft palate  
Upper gingiva   
Lower gingiva   
Tongue   
Floor of mouth  
 Labial mucosa  
Posterior pharynx  
Anogenital  
Total   (  /120)  
 
1 Skin activity  
2 Damage score  
3 Scalp score  
4 Mucosal score  
5 Total PDAI (1+2+3+4) (  /263)  
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ANNEXURE 3  
INFORMED CONSENT FORMS  
PATIENT  INFORMATION  SHEET 
TITLE : STUDY OF HLA DR AND DQ TYPES IN  PATIENTS WITH PEMPHIGUS 
COMPARED TO THAT IN HEALTHY SUBJECTS. 
We are doing a study on patients with pemphigus. Pemphigus is the name given to a group of 
diseases that cause blisters on the skin and erosions in the mouth 
1.. Patients with  this disease  have been found to have certain types of Human Leukocyte 
Antigen (HLA).  HLA is the name given to genes that  are related to immune system function 
(the system that fights against infections in our body).    There are many types of HLA of 
which HLA DR and DQ types are associated with  pemphigus. These HLAs  have been 
reported in studies done in other countries.   
We are doing this study to find out if these types of HLA are  more common in Indian 
patients with pemphigus.  
To find out the HLA type we will be taking 9mL of blood sample from your arm using a 
needle and syringe.  For this study purpose blood sample from you will be taken only 
once.The test might provide knowledge about the  reasons for developing this disease. 
2. .  The severity of the disease can be assessed by certain laboratory parameters which 
includes the  immunoglobulin G4 levels in the blood.  
IgG4 is a protein  that is produced  normally by the body in low levels, it can be found in 
highly increased amounts during disease process.  Higher levels of the antibody suggests a 
more active disease.    To find out the serum IgG4 levels we will be taking 3mL of blood 
sample from your arm using a needle and syringe. The test is done in all patients with 
pemphigus alongwith other routine  blood tests. It is not associated with any significant  
adverse events. Based on the IgG4 levels in your blood   the dose and the duration of your 
therapy might change.  We are inviting all patients with pemphigus to participate in our 
study.   
The information that we collect from you in  this research project will be kept safe with us 
and no-one other than the reseachers will be able to see it.  If this study is published your  
identity will not be revealed. Your participation in the study is voluntary and you can  choose  
not to participate in the study at any time.   Your treatment will continue without any change 
if you choose not to participate in the study. 
If you have any questions you may ask them now or later, even after the study has started. If  
you wish to ask questions later, you may contact us at the following: 
Dr.Anuradha Priyadarshini 
Postgraduate registrar, Dept of Dermatology, Christian Medical College, Vellore. Phone - 
0416-2283527.  Email -  anupriyadarshini@gmail.com 
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PARTICIPANT INFORMATION SHEET (FOR CONTROLS) 
 TITLE: STUDY OF HLA DR AND DQ TYPES IN PATIENTS WITH PEMPHIGUS 
COMPARED TO THAT IN HEALTHY SUBJECTS 
 
We are conducting a study on patients with pemphigus. Pemphigus is a skin disease that is 
associated with blisters on the skin and ulcers in the mouth. The exact cause of this disease is 
not known but it has been seen that patients with pemphigus have certain specific types of 
HLA.  HLA (Human Leukocyte Antigen) is the name given to genes that are related to 
immune system function (the system that fights against infections in our body).    There are 
many types of HLA of which HLA DR and DQ types are associated with pemphigus. These 
HLAs have been reported in studies done in other countries.   
We are doing this study to find out if these types of HLA are more common in Indian patients 
with pemphigus.  
To compare the frequency of these HLA types with normal people we wish to use the results 
of the HLA tests that have been done on you for the purpose of HLA matching while you 
were donating the organ for your relative.     
The use of this data will not affect the treatment of your relative. 
The information that we collect from you in this research project will be kept safe with us and 
no-one other than the reseachers will be able to see it.  If this study is published your identity 
will not be revealed. 
You will not gain anything by participating in this study. But the study might provide 
knowledge about the reasons for developing this disease.  
Your participation in the study is voluntary and you can choose not to participate in the study 
at any time. I am mailing you the consent letter. Kindly sign it and mail it back.  
If you have any questions you may ask them now or later.  If you wish to ask questions later, 
you may contact us at the following: 
Dr.AnuradhaPriyadarshini 
Postgraduate registrar, Dept of Dermatology, Venereology and Leprosy, 
Christian Medical College, Vellore 632004 
Phone - 0416-2283527. 
Email -  anupriyadarshini@gmail.com 
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INFORMED CONSENT FORM 
 
Study Title: :  To study  the HLA DR and DQ types in patients with pemphigus as 
compared to that in healthy subjects 
 
Study Number: ____________ 
Subject’s Name:  _________________________________________ 
Date of Birth / Age: _________________________ 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions.  
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission to 
look at my health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published.  
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
(v)  I agree to take part in the above study.  
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative 
 
Signature: _________________________________                                           Date: 
_____/_____/______ 
 
Signatory’s Name: _________________________________          
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Signature of the Investigator: ________________________             Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature of the Witness: ___________________________                   Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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ANNEXURE 4 
HLA DR AND DQ TYPING BY PCR –SSOP METHOD 
 
PRINCIPLE: 
PCR amplification of DNA is used as the means to enrich selected DNA region. 
During the initial cycles of amplification step, double stranded DNAs are generated. On the 
exhaustion of the limiting primer, the remaining primer uses the double stranded product as 
template for generation of single-stranded DNA. SSO typing procedure is based on the 
hybridization of labeled single stranded PCR product to SSO probes. Each of the different 
probes is designed so that each probe preferentially hybridizes to a complementary region 
that may or may not be present in the amplified DNA.   
 
Different probes are attached to up to 100 different colored Luminex Microspheres, 
designed for use with the Luminex instrument.  The Luminex instrument is able distinguish 
each microsphere and quantify the relative amounts of labeled PCR product hybridizing to 
each Luminex microsphere.  Therefore, the relative signal obtained with the SSO probes can 
be used to assign the probes as having positive or negative reactivity with the amplified DNA 
sample.  This in turn provides the information needed to determine the HLA phenotype of the 
sample.   
 
The beads are analyzed using the Luminex Flow Analyzer and the Luminex IS 
software.  The Quick type for Life match software is then used to evaluate specimens for 
reactivity and print the reports.   
 
SAMPLING AND STORAGE: 
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DNA:  The genomic DNA is extracted from the blood using Salting-out technique (refer 
DNA extraction protocol).  The concentration of the DNA is adjusted to 150 ŋg /l using the 
formula 15 X 200 / the total concentration of the DNA. 
 
We need 150 ŋg /l of DNA i.e. 10l of diluted DNA for each test well. 
Storage: The micro tube containing the assayed DNA is stored at –80 C freezers to maintain 
the integrity of the DNA.  
 
MATERIALS: 
Luminex Flow Analyzer with Luminex IS and Quicktype for Lifematch software  
ABI Thermal cyclers 
Vortex 
Water baths with 37 C and 56 C temperature. 
PCR tubes and caps 
Thermal cycler (PCR) 96 well plates 
Micro seal Film  
Barrier filter tips 
Pipettes  Variable pipettes – (10-1000l), (0-10l), (5-50l), (20-200l). 
Multi-channel pipettes 
 
REAGENTS: 
Recombinant Taq Polymerase 
Nuclease-Free Water 
LIFECODE  HLA-DRB1 Typing test kit consist of 
1. Lifecode HLA DRB Mastermix 
2. Lifecode HLA DRB Probemix 
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LIFECODE  HLA-DQB Typing test kit consist of 
3. Lifecode HLA DQB Mastermix 
4. Lifecode HLA DQB Probemix 
Lifecode R-Phycoerythrin Conjugated Streptavidin (SA-PE) 
 
PROCEDURE 
Preparation OfMastermix:  
1. The mastermix that is stored at 2 – 8 C, should be taken out from storage just prior to 
use. 
2. Take out the mastermix from the corresponding kit box. Place the mastermix in 37 C 
water bath for 10 minutes (to warm up). 
3. Requirement for each test is,  
                   24.5 l of water/well 
       15 l of the appropriate mastermix/well 
0.5 l of Taq/well. 
 While preparing the mix, the required volume of the above reagents per panel is calculated 
as per the Number of tests + Negative control + 1 well extra (to account for pipetting error). 
 
 
 
Amplification: 
1. Take an 8 -cap strip (Micro amp; Applied Biosystems)  
2. Cut to separate the number of wells required.                       
3. Label the wells visibly with the DNA sample number on the sides, and the panel ID. 
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4. Place the wells in the rack.         
5. Add  10l of diluted DNA of the patient horizontally. 
6. Add 40 l of the corresponding mastermix in the wells vertically. 
7. Add cover with seal. 
8. Check tubes to ensure proper pipetting.  If necessary, tap tubes to make sure all reagents 
are at the bottom of the tube. 
9. Cap tubes tightly to prevent evaporation during PCR run. 
10. The final volume must be 50l. Place the tubes in the thermal cycler. 
11. Press the programme for Luminex amplification, which is as follows. 
 
 
 
 
 
 
 
 
 
 
Hybridisation : 
       The probe mix is stored in the fridge at 2 – 4 C for 10 minutes prior to use, take out the 
probe mixers from the respective box and keep in the water bath at 56C.  
 
       Meanwhile, label the coaster plate in a fashion similar to placement of the wells in the 
rack previously i.e. samples assigned to rows and panels to columns. (See diagram)            
   95o C for 5 min 
Number of cycles: 1 
   95o C for 30 sec 
   60o C for 45 sec 
   72o C for 45 sec 
Number of cycles: 8 
   95o C for 30 sec 
   63o C for 45 sec 
   72o C for 45 sec 
Number of cycles: 32 
   72o C for 15 min 
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1. Vortex and add 15 l of probe mix to the wells  
2. Then add 5 l of the amplified product to the test wells. 
3. Seal with the coaster seal provided. 
4. Place them in the Thermal cycler and start the hybridization programme, which is as 
follows. 
 
 
 
 
 
5. When 10 minutes is to over, prepare SAPE. 
 
SAPE Preparation: 
1. The SAPE is kept in the fridge at 2 – 4 C. It must be vortexed before use.         The 
solution is prepared as follows 
2. Dilution solution provided in the kit –170 l/well. 
3. SAPE                                            --- 0.85 l/well. 
4. Calculation of the quantity required per panel eg. ( 3 Tests + 1 NC + 1 extra well)  
5. After preparation of the solution, it must be kept in the dark till use. 
6. When the run is over, do not remove the plate from the Thermal cycler. Immediately, 
add 170 ul of the prepared SAPE solution to each well while the coaster plate is at 56 
on the Thermal cycler. 
7. Then, without delay, take the coaster plate and put it on the metal plate provided in 
Luminex XYZ platform. Click ‘Start. Plate’ on the software to start the run. 
 
   95o C for 5 min 
   47o C for 30 min 
   56o C for 10 min 
       56o C HOLD 
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Interpretation of the results: 
Analysis is comprised of the following steps:       
1.  Verify that the number of events for each SSO in each sample is at least 6. This 
information is found in the Data type : count section of the CSV file. 
2.   Determine that the values for the consensus probes for each sample are above their 
minimum Median Fluoroscent Intensity or  MFI. 
The minimum thresholds are lot specific and can be found in the threshold table. 
3.   Subtract the Background Control value for each probe from the sample values 
producing the background corrected data set.  Background values are average MFI 
values for each bead to compensate for background noise due to bead variation. 
4.   For each sample, divide the background-corrected data for each probe by the 
background-corrected value for the corresponding consensus probe producing the 
normalized data set. 
 
 
 
MFI (probe) – MFI (control blank for probe) 
MFI (consensus) – MFI (control blank for consensus) 
1.   For each probe, record the normalized value on the Threshold Table Worksheet. 
2.   Once all values have been assigned, the probe hit pattern (i.e., the combination of all 
positive and negative assignments for a given sample) can be compared with the Probe 
Hit Table provided. 
 
References: www.gen-probe.com/lifecodes/documents 
                     Product insert – Lifecodes HLA-SSO typing kits for use with Luminex 
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ANNEXURE 5 
Serum  Total  Ig4 Level  Estimation  
 
MININEPHHuman IgG4 Kit, product code ZK009.L.R, the Binding Site. 
Principle :  The determination of soluble antigen concentration by nephelometric method 
involves a reaction with antibody bound to latex particle to form insoluble complexes. When 
light is passed through the suspension formed a portion of the light is scattered and detected 
by a photodiode. The amount of light scattered is directly roportional to the specific protein 
concentration in the test sample. Concentrations are automatically calculated by reference to 
a calibration curve stored within this instrument. 
Sample: Blood sample collected by venipuncture is allowed to clot naturally and serum 
separated as soon as possible to prevent hemolysis. Sera is stored at 2-8⁰C for upto 2 days or 
aliquot and freeze at -20⁰C or below. Dilutions are prespared on the say of assay. 
Reagents ; 
1. Human IgG4 reagent – monospecific antiserum coated onto polystyrene microparticles, 
supplied in lyophilized form.  
2. Minineph IgG4 swipe card  - encoded with details of reaction curve specific to respective 
lot of reagent 
3. Buffer  
4. High and low controls of pooled serum 
 
Procedure :Summary of reagent volumes added to the cuvette ; 
Reagent  Volume added 
Sample (1/121 dilution) 20µL 
Buffer 400µL 
IgG4 reagent 40µL 
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The analyzer is switched on and the chemistry number (IgG4 =9) is entered. 
The chemistry card is swiped and the lot number is checked. 
Dilutions of controls and samples using the sample diluent is prepared, recommended 
dilution of 1/121. 
 
Cuvettes are prepared with 20µL of sample to which 400µL of buffer and 40µL of reagent 
are added, it is stirred and placed in the cuvette chamber.  
 
Once the buffer and reagent are added and stirred, it is detected by the device and the assay 
begins. The results are printed out  after 165seconds. 
 
If the result is higher than the measuring range the sample is re-assayed at higher dilutions. If 
it is lower than the measuring range the sample is re-assayed at lower dilutions. 
 
Interpretation of results : 
Results are calculated by the instrument and displayed in mg/L.  
Sample concentrations up to at least 3350mg/L will not result in antigen excess. Higher 
concentrations may give misleading results and should be re-assayed with dilutions.  
 
Limitations  :Nephelometric assays are not suitable for high lipemic or hemolysed samples 
or samples containing high levels of circulating immune complexes due to unpredictable 
degree of  non-specific scatter these sample types may generate.  
 
Expected results : 
The IgG4 results obtained with normal adult donor sera is mean = 426m/L, median  
= 423mg/L, 95th percentile range = 62-1127 mg/L 
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ANNEXURE 6 
 
KEY TO MASTERCHART  
Sno-  study number  
Pv- Pemphigus vulgaris, pf-pemphigus foliaceus, cc-controls 
 
Hosp- hospital number 
  Age- age of patient, in years 
Gend- gender of the patient,  
1=male, 2=female 
  Place-place of residence,  
1=TN Tamil nadu,  2=AP AndhraPradesh 3=kerala 4=westbengal 5=bihar 
6=jharkhand 7=chattisgarh 8=others ( 
 
 Visit- first or review visit,  
1=first visit 2=review visit  
 
 Duran- duration of diesase in years   
 
Onst-site of onset of lesions,  
1=oral, 2=skin,  3=scalp 
 
Symp- presenting symptom at disease onset  
 1= pain, 2=burning,  3=itching,  4=pain and burning,  5=pain and itching,  6=nil 
 
 Photos- history of photosensitivity 
  1=present, 0=absent  
 Drugs-  history of preceding drugs 
 1=present,  0=absent,  2=not known 
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Trtmnt- previous specific treattment received 
 1=yes 0 =no 
 
 Steroid- mode of steroid therapy 
1=oral, 2=intravenous, 3=pulse only, 4=oral +pulse, 5=intramuscular, 
6=oral+intramuscular 
 
Stddos-maximum equvalent dose of oral prednisolone in per kg body weight.                                                
 
Stddur-duration of steroid therapy in yrs 
 
Curntstd – current steroid dose (equivalent per day dose in mg) 
 
Azoran-treated with azathioprine  
1=yes 0-no        
 
Azrndos-dose of azoran in mg /day. 
 
Azrndur - duration of treatment with azathioprine  inyrs 
 
Cyclophosph - treated with cyclophosphamide, 
 1=yes, 0=no 
 
Cyclodos - dose  of cyclophosphamide in mg/day 
 
Cyclodur- duration of treatment cyclophosphamideinyrs 
 
Mmf - treated with Mycophenolatemofetil,  
1=yes, 0=no                 
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Mmfdos- dose of mycophenolatemofetil,  in mg/day 
 
Mmfdur- duration of MMF in yrs 
 
Mtx - treated with methotrexate,  
1=yes, 0=no 
 
Mtxdos- dose of methotrexate in  mg/week 
 
Mtxdur- duration of methotrexate in years   
 
Dapsone- treated with dapsone,  
1=yes, 0=no 
 
Dapdos- dose of dapsone in mg /day 
 
Dapdur- duration of dapsoneinyrs 
 
Ivig - treated with ivig, 
1=yes, 0=no 
 
Rxivig-  number of times treated with ivig 
 
Ritux – treated with rituximab, 
1=yes, 2=no               
 
Rxritux - number of times received rituximab  
 
Comorb- associated comorbidities, 
 1=yes, 0=no             
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DM-diabetes mellitus, 
1=yes,  0=no  
 
Htn- hypertension, 
1=yes,   0=no 
 
Vit D-  hypovitaminosis D,  
1=yes,   0=no 
 
Thyroid – hypothyroidism,  
1=yes 0=no 
 
 Others -  othercomorbids not mentioned above,  
1=yes, 0=no 
 
Othercomor- specify other comorbids   ________________________ 
 
Famhist-  family h/o pemphigus present, 
1=yes,   0=no    
 
Activity - whether in remission or activity 
1=activity, 2=remission 
 
Skin - skin is involved,  
1=yes, 0=no                         
 
 Face - face is involved, 
 1=yes, 0=no  
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Upperl - upper limbs are involved,  
 1=yes, 0=no 
 
Lowerl-  lower limbs are involved  
1=yes,  0=no                   
 
 Trunk -  trunk is involved  
1=yes, 0=no 
 
 Flex - flexures are involved,  
1=yes, 0=no 
 
 Genital -  genital and perineal region involved 
1=yes,  0=no 
 
 Bullae - vesicles and bullae present     
1=present, 0=absent 
 
Erosion  - crusted or moist erosions  
1=present, 0=absent 
 
Vegatns - vegetative lesions 
1=present, 0=absent 
 
 Macules – postinflammatoryhyperpigmented macules 
 1=present, 0=absent 
 
Acanthoma -acanthoma type of lesion 
1=present, 0=absent       
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Scalp - scalp involvement 
1= present, 0= absent 
 
Nails - nails have paronychia  
1=present, 0=absent 
 
Mucosa - mucosal involvement is present  
1= present, 0=absent 
 
Oral - oral mucosal involvement 
1= present, 0=absent 
 
Eye - conjunctival involvement  
1=present  0= absent 
 
Nose - nasal mucosal involvement 
1= present, 2=absent 
 
Anogenital- anogenital mucosal involvement  
1=present 0= absent 
 
Nikolsk - nikolksy sign  
1=positive,  0=negative,  2=not done 
 
Bss  - bulla spread sign   
1=positive,  0=negative,   2= not done 
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Skinact – activity  score in skin (0-120) 
 
Skindam-  damage score in skin (0 -13) 
 
Slpscr–  scalp score  ( 0-10 ) 
 
Mucosscr - mucosal score ( 0-120) 
 
PDAI - total PDAI score  (0-263) 
 
Tzanck - Tzanck smear 
0=negative,  1=acantholytic  cell positive,  2=not done 
 
Biopsy-  biopsy from skin/mucosal lesion  
1=pemphigus vulgaris, 2=pemphigusfoliaceus,  3= not characteristic,  4=not done 
 
DIFiG - Ig type on direct immunofluoresence 
 1=IgG lowerthird of epidermis,  2=IgG lowerhalf,  3=IgG entire epidermis,  4=IgA,  
5= IgG basement membrane,  6=negative, 7=not done 
 
DIFc3 -   complement deposit on direct immunofluorescence; 
1=c3 lower third,  2=c3lower half of epidermis,  3=c3 entire epidermis  4=c3basal 
layers,  5=nil 6=not done 
 
dsg1- anti-desmoglein1 levels 
 
dsg3-  anti-desmoglein3 levels 
 
IgG4 - serum IgG4 levels    
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 HLADR1-  DRB1  1st allele  
 HLADR2-  DRB1 2nd allele  
 HLADQ3 -  DQB1 1st allele  
 HLADQ4- DQB1 2nd allele  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
sno hosp age gend place visit duran onst symp photos drugs trtmnt steroid stddos stddur curntstd 
V1 644014f 46 2 1 2 1.5 1 5 0 0 1 1 1 1 40 
v2 641638f 16 1 4 2 0.5 1 6 0 0 1 1 1.75 0.4 30 
v3 585536d 42 1 7 2 6 1 5 0 0 1 1 1.5 5 20 
V4 708153F 21 2 1 2 1 1 5 0 0 1 1 0.3 1 12.5 
V5 414211D 52 2 1 2 4.5 1 1 0 0 1 1 0.5 4 2.5 
V6 228513F 17 2 1 2 2.5 1 1 0 0 1 1 0.75 2  
V7 704111D 48 2 1 2 3 2 6 1 0 1 4 2 3 1.25 
V8 645738F 42 1 2 2 5 1 1 1 0 1 4 1.3  25 
V9 060980F 45 1 4 2 2.5 1 2 0 0 1 1 1 1.5 2.5 
V10 993076D 58 2 3 2 4 3 1 0 0 1 1 0.75 4 2.5 
V11 236360F 12 1 1 1 0.5 1 3 0 0 1 1 1 0.33 10 
V12 772495F 25 1 4 1 2 1 1 0 0 0     
V13 187349F 63 2 8 2 3 2 3 0 0 1 1 1 2 5 
V14 782767F 52 2 4 1 10 1 3 1 0 1 4  10 5 
V15 212061D 47 2 1 2 8 1 1 0 0 1 1 1.2 7 0 
V16 764284F 28 2 1 2 1.25 1 4 0 0 1 1 1 0.03 50 
V17 261374F 26 2 1 2 2 1 1 0 0 1 1 1 2 0 
V18 301696F 49 2 7 2 2 1 1 0 0 1 1 1 2 2.5 
V19 184977D 47 1 8 2 6 1 2 0 0 1 1 0.6 6 5 
V20 375701F 30 2 1 2 1.5 1 1 0 0 1 1 1 1.33 5 
V21 787130F 50 1 2 1 0.5 3 1 0 0 1 4 1 0.41  
v22 732519d 43 2 4 2 5 1 2 0 0 1 1 1 4 5 
v23 967097d 55 2 1 2 3 1 3 0 0 1 1 1 2.5 5 
v24 115614f 46 2 1 2 2.5 1 1 0 0 1 1 0.75 2 5 
v25 803971f 35 2 4 1 0.3 1 1 0 0 1 1 0.3 0.16 20 
v26 826499f 38 1 1 1 4 1 1 0 0 1 4 0.5 3 0 
v27 498371f 61 2 1 2 1 2 6 0 0 1 1 0.5 1 5 
v28 831251f 30 1 2 1 0.16 1 1 0 0 1 1 1 0.12 60 
v29 314619f 43 1 8 2 1.5 1 4 0 0 1 1 1 1 12.5 
v30 969123c 52 2 1 2 7 1 1 0 1 1 1 1 7 7.5 
v31 635185d 31 1 4 2 5 1 1 0 0 1 1 1.5 4 20 
v32 270080d 29 2 1 2 2 1 4 0 0 1 1 0.8 1  
v33 996621d 39 2 1 2 5 1 1 0 0 1 1 0.75 4 7.5 
v34 342669f 70 1 2 2 2 1 1 0 0 1 1 1 1.5 7.5 
v35 709274d 31 2 1 2 4 2 5 0 0 1 1 1 4 2.5 
v36 855030d 54 1 4 2 3 1 5 0 0 1 1 1 3 5 
v37 847541f 49 1 4 1 3 1 2 0 0 1 1 1 2 20 
v38 653505f 60 1 5 2 1 1 1 0 0 1 5 1 0.66 5 
v39 399599d 66 2 6 2 15 1 1 0 0 1 1 0.5 15 40 
v40 449434f 19 2 4 2 3 1  0 0 1 1 1 2.5 5 
v41 639189d 50 1 2 2 4 3 1 0 0 1 1 1 3 7.5 
v42 841906f 29 2 4 1 1 1 1 0 0 1 1 2 0.66 40 
v43 862487f 56 2 3 1 1 1 2 0 0 0     
v44 871274f 24 1 8 1 0.25 1 5 1 0 0     
v45 875867f 32 2 2 1 0.83 1 4 0 0 1 1 0.6 0.5 5 
v46 885044f 22 2 1 1 2 2  1 0 1 1 0.6 2 10 
v47 885129f 39 2 5 1 1 1 2 0 0 1 1 0.75 0.66 60 
v48 010927g 58 1 7 1 0.41 1 1 0 0 1 4 0.5 0.25  
v49 024603g 44 1 8 1 0.5 1 1 1 0 1 4 0.5 0.33 10 
v50 031237g 42 2 4 1 3 2 3 0 0 1 1 1 2 5 
v51 421333d 57 1 1 2 4.5 1 2 0 0 1 1 1 4 10 
v52 088942f 66 2 5 2 5 1 4 0 0 1 1 1 4 5 
f1 710291d 32 1 1 2 3.5 1 3 0 0 1 1 0.6 3.5 5 
f2 676577d 68 1 1 2 5 3 6 0 0 1 1 1 3 5 
f3 788034f 26 1 6 1 1 2 3 1 0 1 1 0.7 0.8 5 
f4 285308f 27 1 4 2 3.5 2 3 0 0 1 1 2 3 10 
f5 809482f 32 2 4 1 0.5 1 1 1 0 1 4 0.8 0.33 40 
f6 606336f 54 1 4 2 3 2 3 0 0 1 1 1 3 12.5 
f7 831598f 46 2 2 1 0.25 2 1 0 0 1 2 1 0.16 50 
f8 853709f 35 1 8 1 0.33 3 3 0 0 1 1 0.5 0.25 5 
f9 847257d 57 1 4 2 4 3 3 0 0 1 4 1 3.5 10 
f10 733943d 63 1 1 2 6 2 3 0 0 1 1 1 5 5 
f12 749835f 58 1 1 1 0.18 3 3 0 0 0     
f13 768241f 45 1 1 1 0.16 2 5 0 0 1 1 0.2 0.08 5 
f14 914077f 47 2 1 1 3 1 3 0 0 1 4 0.6 2.5 0 
f15 015076g 42 1 3 1 0.6 1 6 0 0 1 1 0.3 0.5 5 
f16 020317g 37 1 8 1 4 2 6 0 0 1 1 0.6 3 0 
f17 799031f 66 1 6 1 0.66 3 3 0 0 1 1 1 0.5 0 
f18 774819f 60 1 4 1 4 3 3 0 0 1 4 0.2 0.25 20 
f19 031057g 46 2 4 1 4 2 2 0 0 1 4 0.6 4  
v53 406207f 37 2 8 2 1.3 1 1 0 0 1 1 1 1.3 5 
v54 017668g 46 1 4 1 2 2 5 0 0 1 1 1.2 2 20 
 
 
 
 
 
 
 
 sno azoran azrndos azrndur cyclophosp cyclodos cyclodur mmf mmfdos mmfdur mtx mtxdos mtxdur dapsone dapdos dapdur 
V1 0   0   0   0   0   
v2 0   0   0   0   0   
v3 1 50 3 0   0   0   0   
V4 1 50 0.5 0   0   0   1 100 0.16 
V5 1 50 3 0   0   0   0   
V6 1 50 0.5 0   0   0   0   
V7 1 50 0.2 0   1 1000 0.75 0   0   
V8 1 50 1.25 0   1 1500 0.08 0   0   
V9 1 75 1 0   0   0   0   
V10 1 100 4 0   0   0   0   
V11 0   0   0   0   0   
V12                
V13 1 50 2 0   0   0   0   
V14 0   0   0   0   1 100 0.2 
V15 0   0   0   0   0   
V16 0   0   0   0   0   
V17 1 50 0.66 0   0   0   0   
V18 1 50 0.83 1 50 0.02 0   0   0   
V19 1 100 5 1 50 0.41 0   0   0   
V20 1 50 0.33 0   0   0   0   
V21 0   0   0   0   0   
v22 0   0   0   0   0   
v23 1 50 2 0   0   0   0   
v24 1 25 1.5 0   0   0   0   
v25 0   0   0   0   0   
v26 0   1 50 2.5 0   0   0   
v27 0   0   0   0   1 100 0.12 
v28 0   0   0   0   1 100 0.12 
v29 1 25 1 0   0   0   0   
v30 1 50 1 0   0   0   0   
v31 1 50 1.5 0   0   0   1 100 1 
v32                
v33 1 50 0.12 1 75 0.5 0   0   1 100 0.16 
v34 1 50 0.16 0   0   0   0   
v35 0   0   0   0   0   
v36 1 50 2 0   0   0   0   
v37 1 50 0.66 1 50 0.5 0   0   0   
v38 1 100 0.66 0   0   0   0   
v39 0   0   0   1 5 2 0   
v40 1 50 2 0   0   0   0   
v41 1 100 0.25 0   0   0   0   
v42 0   0   0   0   0   
v43                
v44                
v45 0   0   0   0   0   
v46 0   1 50 0.33 0   1 7.5 0.12 1 100 2 
v47 1 100 0.25 0   0   0   0   
v48 0   1 50 0.16 0   0   0   
v49 0   1 50 0.03 0   0   0   
v50 1 100 1.5 0   0   0   0   
v51                
v52 1 50 0.6 0   0   0   0   
f1 1 50 3 0   0   0   0   
f2 1 50 0.25 1 200 0.33 0   1 7.5 0.5 1 50 0.25 
f3 0   0   0   1 7.5 0.08 0   
f4 1 50 0.25 0   0   0   0   
f5 1 50 0.33 0   0   0   0   
f6 0   0   0   1 15 1.5 1 50 1 
f7 0   0   0   0   0   
f8 0   0   0   0   0   
f9 1 50 0.5 0   0   0   0   
f10 0   0   0   0   1 100 4 
f12                
f13 0   0   0   0   0   
f14 0   1 50 2 0   0   0   
f15 0   0   0   0   0   
f16 1 150 2 1 100 0.25 0   0   0   
f17 0   0   0   0   0   
f18 1 50 0.03 1 100 0.08 0   0   1 100 0.08 
f19 0   1 50 4 0   0   0   
v53 1 50 0.5 0   0   0   0   
v54 1 50 1 0   0   0   0   
 
 
 
 
 
 
 
 
 sno ivig rxivig ritux rxritux comorb dm htn vitd thyroid others othercomor famhist activity skin face 
V1 0  0 0 1 0 0 0 0 1 asthma  0 1 1 1 
v2 0  0 0 0       0 1 1 0 
v3 0  0 0 1 0 1 0 0 1 osteoporosis 0 1 1 1 
V4 0  0 0 1 0 0 0 0 1 atopy 0 1 0  
V5 0  0  1 1 1 0 0 0  0 1 1 0 
V6 0  0  0       0 1 1 0 
V7 1 1 0  1 0 0 0 1 0  0 2   
V8 0  0  1 0 0 0 0 1 hiv 0 1 1 1 
V9 0  0  0       0 2   
V10 0  0  1 1 1 1 0 0  0 2   
V11 0  0  1 0 0 1 0 0  0 1 1 1 
V12     0       0 1 0  
V13 0  0  1 1 1 1 0 1 osteoporosis 0 2   
V14 0  0  1 0 1 0 0 0  0 2   
V15 0  0  1 1 1 0 0 0  0 1 1 0 
V16 0  0  0       0 1 0  
V17 0  0  1 0 0 1 0 1  0 1 1 1 
V18 0  0  1 0 1 1 0 0  0 2   
V19 0  0  1 0 0 1 0 0  0 1 0  
V20 0  0  0       0 1 0  
V21 0  0  0       0 1 1 1 
v22 0  0  0       0 1 0  
v23 0  0  1 1 1 0 0 0  0 2   
v24 0  0  0       0 2   
v25 0  0  1 0 0 1 0 0  0 1 1 0 
v26 0  0  1 0 0 1 0 0  0 1 1 1 
v27 0  0  1 0 0 0 0 1 nhl 
retroperitonealfibro 
0 2   
v28 0  0  1 0 0 1 0 0  0 1 1 1 
v29 0  0  1 0 1 1 0 1  0 1 0  
v30 0  0  0       0 1 0  
v31 0  0  1 0 0 0 0 1 osteopenia 0 1 1 1 
v32                
v33 0  0  0       0 1 1 1 
v34 0  0  1 1 1 1 0 0  0 1 1 1 
v35 0  0  1 0 0 1 0 0  0 1 0  
v36 0  0  1 0 1 0 0 0  0 1 1 0 
v37 0  0  1 0 0 0 0 1 osteopenia 0 1 1 1 
v38 0  0  1 0 0 1 0 0  0 1 1 1 
v39 0  0  1 1 1 1 0 0  0 1 1 0 
v40 0  0  0       0 2   
v41 0  0  1 1 1 0 0   0 1 1 0 
v42 0  0  1 1 0 1 0 1 osteopenia  0 1 1 1 
v43     1 1 0 0 0 1 osteoporosis dyslipid 0 1 1 0 
v44     1 0 0 1 0 0  0 1 1 0 
v45 0  0  0       0 1 1 1 
v46 0  0  1 0 0 0 0 0  0 1 1 1 
v47 0  0  1 1 1 1 1 0  0 1 1 0 
v48 0  0  1 0 0 1 0 0  0 1 1 1 
v49 0  0  1 0 0 1 0 0  0 1 1 0 
v50 0  0  1 0 0 1 0 0  0 1 1 1 
v51     1 1 1 0 0 1 hepatitis c  0 1 1 1 
v52 0  0  1 1 0 1 0 1 osteopenia 0 1 1 0 
f1 0  0  0       0 1 1 1 
f2 0  0  0       0 1 1 1 
f3 0  0  0       0 1 1 1 
f4 0  0  1 1 0 0 0 1 Osteopenia 0 1 1 1 
f5 0  0  1 0 0 1 0 0  0 1 1 1 
f6 0  0  1 1 1 0 0 0  0 1 1 0 
f7 0  0  0       0 1 1 1 
f8 0  0  1 1 0 0 0 0  0 1 1 1 
f9 0  0  1 1 0 0 0 1 chronic liver disease 0 1 1 0 
f10 0  0  1 0 1 0 0 1 adjustment disorder 0 1 1 0 
f12     1 1 1 0 0 0  0 1 1 1 
f13 0  0  1 1 0 1 0 0  0 1 1 1 
f14 0  0  1 1 0 0 1 0  0 1 1 1 
f15 0  0  0       0 1 1 0 
f16 0  0  1 1 0 0 0 1 tuberculosis 0 1 1 1 
f17 0  0  1 1 0 1 0 0  0 1 1 1 
f18 0  0  1 1 0 1 0 0  0 1 1 1 
f19 0  0  1 1 0 1 0 1 osteoporosis 0 1 1 0 
v53 0  0  0       0 1 0  
v54 0  0  1 0 0 1 0 1 osteoporosis 0 1 1 1 
 
 
 
 
 
 
 
sno upperl lowerl trunk flex genital bullae erosion vegatns macules acanthoma scalp nails mucosa oral eye nose anogenital 
V1 1 1 1 0 0 1 1 0 0 0 1 0 1 1 0 0 0 
v2 1 1 1 0 1 1 1 0 1 0 1 0 1 1 0 0 1 
v3 1 1 1 0 0 0 1 0 1 0 0 1 1 1 0 0 0 
V4           0 0 1 1 0 0 0 
V5 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 0 
V6 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 0 
V7                  
V8 0 0 1 0 0 0 1 0 1 0 1 0 1 1 0 0 1 
V9                  
V10                  
V11 1 1 1 1 0 0 1 0 1 0 1 0 0     
V12           0 0 1 1 0 0 0 
V13                  
V14                  
V15 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 0 
V16           0 0 1 1 0 0 0 
V17 1 1 1 0 0 0 1 0 1 0 0 0 1 1 0 0 0 
V18                  
V19           0 0 1 1 0 0 0 
V20           0 0 1 1 0 0 0 
V21 1 1 1 0 0 1 1 0 1 0 1 0 1 1 1 0 0 
v22           0 0 1 1 0 0 0 
v23                  
v24                  
v25 1 1 1 0 0 1 1 0 1 0 1 0 1 1 0 0 1 
v26 1 0 1 1 0 0 1 0 1 0 1 1 1 1 0 0 1 
v27                  
v28 1 1 1 1 1 1 1 0 1 0 1 0 1 1 0 0 0 
v29           0 0 1 1 0 0 0 
v30           0 0 1 1 0 0 0 
v31 1 1 1 0 0 1 1 0 1 0 1 0 1 1 0 0 0 
v32                  
v33 1 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 0 
v34 0 0 1 0 0 0 1 0 1 0 0 0 1     
v35           1 0 1 1 0 0 0 
v36 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 0 
v37 0 0 1 0 0 0 1 0 1 0 1 0 1 1 0 0 0 
v38 1 0 1 0 0 0 1 0 1 0 0 0 1 1 0 0 0 
v39 0 0 0 1 0 0 1 0 0 0 0 0 0     
v40                  
v41 0 0 1 0 0 0 0 0 1 0 1 0 0     
v42 0 0 1 0 0 0 1 0 1 0 1 0 0     
v43 0 0 1 0 0 0 1 0 1 0 0 0 1 1 0 0 0 
v44 0 0 1 0 0 1 1 0 1 0 0 0 1 1 0 0 0 
v45 1 1 1 1 0 1 1 0 1 0 1 0 1 1 0 1 0 
v46 1 1 1 1 1 1 1 0 1 0 1 1 1 1 0 0 0 
v47 1 0 1 1 0 0 1 1 1 0 1 1 1 1 0 0 0 
v48 1 1 1 1 0 1 1 0 1 0 1 1 1 1 0 0 0 
v49 1 1 1 1 1 1 1 1 1 0 0 1 1 1 0 0 1 
v50 1 1 1 1 0 1 1 1 1 0 0 0 0     
v51 1 1 0 0 0 0 1 0 1 0 1 0 0     
v52 1 1 1 0 0 1 1 0 1 0 1 1 1 1 0 0 0 
f1 0 0 0 0 0 0 1 0 1 0 0 0 0     
f2 1 1 1 0 0 0 1 0 1 0 1 0 0     
f3 1 1 1 1 0 1 1 0 1 0 1 1 0     
f4 1 0 1 0 0 0 1 0 1 0 0 0 0     
f5 1 1 1 1 1 1 1 0 0 0 1 0 0     
f6 1 0 1 0 0 0 0 0 1 0 0 0 0     
f7 1 1 1 1 0 1 1 0 0 0 1 0 0     
f8 1 1 1 0 0 1 1 0 1 0 1 0 0     
f9 1 0 1 0 0 0 1 0 1 0 1 0 0     
f10 1 0 1 0 0 1 1 0 1 0 0 0 0     
f12 1 1 1 0 0 1 1 0 1 0 1 0 0     
f13 1 0 1 0 0 1 1 0 0 0 1 0 0     
f14 1 1 1 1 1 1 1 0 1 0 1 0 0     
f15 1 0 1 0 0 0 1 0 1 0 0 0 0     
f16 1 0 1 1 0 0 1 0 1 0 1 0 0     
f17 1 1 1 1 0 0 1 0 0 0 1 0 0     
f18 1 0 1 0 0 0 1 0 1 0 1 0 0     
f19 1 1 1 0 0 1 1 0 1 0 1 0 0     
v53           0 0 1 1 0 0 0 
v54 1 0 1 1 0 0 1 0 1 0 1 0 0     
 
 
 
 
 
 
 
 
 
 sno nikolsk bss skinact skindam slpscr mucosscr PDAI tzanck biopsy difig difc3 dsg1 dsg3 igg4 
V1 0 1 50 0 3 1 54 1 1 2 2 210 156 1150 
v2 0 1 43 4 1 12 60 2 1 2 2 147 173  
v3 0 2 3 6 0 12 21 2 4 7 6 135 161 786 
V4 2 2 0 2 0 5 7 0 1 3 5 85 155  
V5 2 2 0 4 0 1 5 2 1 2 2 2 122 1365 
V6 0 2 0 2 0 15 17 1 1 2 4 13 160 760 
V7        2 1 2 4 6.3 7.1  
V8 0 0 10 3 10 25 48 2 2 7 6 49 143 748 
V9        2 4 7 6 7.6 170  
V10        2 4 7 6 5.5 211  
V11 0 1 16 3 3 0 22 2 3 1 5 43 202 1299 
V12 2 2 0 0 0 3 3 2 1 1 1 12.2 176 1033 
V13        1 1 1 5 2 2  
V14        2 4 7 6 15.2 122  
V15 2 2 0 3 0 1 4 2 1 2 2 1.5 99 704 
V16 2 2 0 0 0 5 5 1 4 6 5 8 166 1898 
V17 0 0 19 6 3 18 46 2 1 1 5 182 185 923 
V18        2 1 1 5 2 67.4  
V19 2 2 0 0 0 3 3 2 1 3 1 2 143 760 
V20 2 2 0 0 0 1 1 2 4 2 5 4.5 187 713 
V21 1 1 31 6 4 4 45 2 1 2 2 190 202 1829 
v22 2 2 0 0 0 5 5 2 1 2 4 15 4.2 1829 
v23        2 4 2 5    
v24        1 1 6 5 3.8 4.8  
v25 0 0 10 4 3 57 74 1 1 1 1 148 169 605 
v26 1 2 3 1 3 11 18 1 2 5 4 2.3 195  
v27        1 3 2 5 2 16.4  
v28 1 1 49 8 1 17 75 0 1 3 4 72 144 601 
v29 2 2 0 0 0 1 1 1 1 1 4 2 14 596 
v30 2 2 0 0 0 7 7 1 1 3 4 31.3 194 1557 
v31 1 1 26 7 1 5 39 1 1 2 4 256 200 1463 
v32         1 2 2    
v33 2 2 0 3 0 3 6 0 1 1 5 5.6 79 715 
v34        0 1 1 4 161 144 1426 
v35 2 2 0 0 1 3 4 1 1 2 5 29 198  
v36 0 0 0 1 0 2 3 2 1 6 2 2 66 672 
v37 0 0 4 2 3 2 11 2 1 2 2 260 252 3199 
v38 0 0 4 3 0 3 10 2 4 2 2 2.2 249 1201 
v39 0 0 2 0 0 0 2 2 1 1 1 2 2 698 
v40        1 1 2 4 2 11 758 
v41 0 0 0 1 1 0 2 2 1 6 5 68.5 76.3 605 
v42 0 0 11 8 1 0 20 1 1 1 1 14.7 243 605 
v43 0 0 2 2 0 3 7 2 1 6 5 151 121 772 
v44 1 1 10 2 0 36 48 2 1 1 1 3.06 248 1964 
v45 0 0 13 9 3 25 50 1 1 2 2 9.2 257 1749 
v46 1 1 40 11 4 2 57 1 1 2 2 180 256 881 
v47 0 2 10 7 3 12 32 1 3 2 4 66 250 646 
v48 0 1 10 7 3 15 35 0 4 2 1 127 261 813 
v49 0 0 20 4 0 51 75 0 1 2 2 37 221 902 
v50 0 0 2 3 0 0 5 2 4 7 6 51 249 602 
v51 0 2 9 4 10 0 23 1 1 1 1 267 250 2224 
v52 0 0 13 7 2 5 27 1 1 1 1    
f1 0 2 2 1 0 0 3 1 2 2 4 146 2 605 
f2 0 2 5 9 1 0 15 1 2 3 5 200 2 754 
f3 1 1 32 6 4  41 1 4 3 3 166 86 714 
f4 0 2 3 3 0 0 6 0 4 3 5 163 2.1 1898 
f5 1 1 95 0 10 0 105 1 4 3 1 234 117 7378 
f6 0 2 0 3 0 0 3 0 2 3 3 26.4 2 602 
f7 1 1 85 0 3 0 88 0 4 2 2 223 163 617 
f8 0 1 11 6 1 0 18 0 2 2 2 291 2.2 892 
f9 0 0 5 6 1 0 12 2 2 3 3 130 2.5 1263 
f10 0 0 17 6 0 0 23 1 2 2 2 204 32 605 
f12 1 1 18 2 10 0 30 1 2 3 3 150 29 605 
f13 1 1 26 0 4 0 30 1 4 3 3 234 94 1518 
f14 1 1 70 7 4 0 81 1 2 3 3 242 3 605 
f15 0 0 2 2 0 0 4 2 2 3 5 136 2 1475 
f16 1 2 22 10 10 0 42 1 4 2 2 231 0 605 
f17 1 2 37 0 4 0 41 0 2 3 3 1 1 1610 
f18 1 2 30 7 10 0 47 1 2 3 2 234 33 2881 
f19 0 2 11 6 3 0 20 2 2 2 2   990 
v53 2 2 0 0 0 2 2 2 1 7 6 2 19.4 894 
v54 0 0 3 5 3 0 11 2 4 2 2 5.3 94 1007 
 
 
 
 
 
 
 
 
  
sno hospno DRB1a DQB1a DRB1b  DQB1b s  no. hospno DRB1a DQB1a DRB1a DQB1b 
V1 
644014f 
11 03 14 05 C1 431684f 09 03 10 05 
V2 
641638f 
04 03 14 05 C2 369860f 13 06 03 02 
V3 
585536d 
10 05 14 05 C3 340733f 15 06 15 06 
V4 
708153F 
08 03 14 05  C4 404040f 12 03 14 05 
V5 
414211D 
14 05 15 06 C5 144058f 04 02 07 03 
V6 
228513F 
07 03 14 05 C6 776406d 07 02 11 03 
V7 
704111D 
07 02 14 05 C7 448672f 03 02 14 05 
V8 
645738F 
04 03 14 05 C8 402692f 15 06 15 06 
V9 
060980F 
07 03 14 05 C9 441411f 14 05 13 06 
V10 
993076D 
04 03 14 05 C10 426140f 07 03 10 05 
V11 
236360F 
14 05 14 05 C11 457016f 07 03 11 02 
V12 
772495F 
14 05 14 05 C12 495996f 08 03 14 05 
V13 
187349F 
04 03 07 03 C13 409926f 13 05 15 06 
V14 
782767F 
12 03 14 05 C14 624827f 14 05 14 05 
V15 
212061D 
14 05 14 05 C15 465678f 15 06 15 06 
V16 
764284F 
14 05 15 06 C16 491652f 04 03 13 06 
V17 
261374F 
14 05 14 05 C17 492596f 12 03 14 05 
V18 
301696F 
04 03 14 05 C18 931164c 15 06 11 03 
V19 
184977D 
04 03 10 05 C19 049725c 07 02 13 06 
V20 
375701F 
07 03 14 05 C20 206513d 07 02 07 02 
V21 
787130F 
04 03 14 05 C21 675880f 07 03 12 03 
V22 
732519d 
12 03 14 05 C22 650207f 01 03 04 05 
V23 
967097d 
04 03 14 05 C23 418943f 15 06 14 05 
V24 
115614f 
04 03 14 05 C24 694842c 13 05 14 06 
V25 
803971f 
07 03 14 05 C25 623729f 14 05 07 02 
V26 826499f 13 05 14 06 C26 714904f 04 03 12 04 
V27 498371f 03 02 15 06 C27 647570f 07 03 14 05 
V28 831251f 14 05 15 06 C28 729495f 04 03 15 06 
V29 314619f 08 04 14 05 C29 750412f 11 03 12 03 
V30 969123c 14 05 14 05 C30 206907d 10 05 15 06 
V31 635185d 11 03 14 05 C31 769727f 12 03 11 03 
V33 996621d 14 05 14 05 C32 722988f 15 05 15 06 
V35 709274d 04 04 14 05 C33 784197f 04 03 11 03 
V36 855030d 14 05 15 05 C34 700890f 01 03 07 05 
V37 847541f 07 02 14 05 C35 766321f 11 03 14 05 
 V38 653505f 14 05 15 06 C36 632549f 11 03 15 06 
V40 449434f 12 03 14 05 C37 605972f 14 05 15 06 
V41 639189d 14 05 14 05 C38 037534f 15 06 10 05 
V42 841906f 14 03 14 05 C39 499704f 15 05 14 05 
V43 862487f 14 05 16 05 C40 792128f 01 05 10 05 
V44 871274f 14 05 15 05 C41 616181f 14 05 15 05 
V45 875867f 08 04 14 05 C42 753831f 14 05 15 06 
V46 885044f 08 03 14 05 C43 670039f 04 03 12 03 
V48 010927g 14 03 14 05 C44 801004f 12 03 15 06 
V49 024603g 04 03 14 05 C45 783347f 07 03 12 03 
V50 031237f 07 02 14 05 C46 819431f 07 02 14 05 
V51 421333d 04 03 14 05 C47 492570f 11 03 11 03 
V52 088942f 13 06 14 06 C48 743932f 07 03 07 02 
V53 406207f 14 05 15 06 C49 023624f 12 03 04 03 
V54 017668g 04 03 14 05 C50 053531f 07 02 07 02 
